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Sommario 
I carcinomi spinocellulari (o a cellule squamose) sono le malattie umane più 
comuni che si verificano negli adulti di carnagione chiara e rappresentano circa il 
30% dei tumori totali nel mondo. L'eziologia di questo tipo di cancro è 
multifattoriale, dal momento che fattori genotipici, fenotipici e/ o ambientali possono 
essere coinvolti nel suo sviluppo.  
Diversi studi hanno messo in evidenza che l'esposizione ai raggi ultravioletti (UVB) 
rappresenta un fattore di rischio chiave nello sviluppo del cancro della pelle. Inoltre, 
gli agenti infettivi potrebbero costituire un ulteriore fattore di rischio, ipotesi 
sostenuta dal fatto che i pazienti immunocompromessi, quali ad esempio i soggetti 
che hanno subito un trapianto di organo (OTR), mostrano un rischio più elevato di 
sviluppare carcinomi spinocellulari rispetto agli individui immunocompetenti. Molti 
agenti infettivi sono in grado di colonizzare la pelle e in particolare un sottogruppo 
di beta papillomavirus umani a tropismo cutaneo (β-HPV) è considerato il fattore 
eziologico più probabile nello sviluppo del carcinoma a cellule squamose.  
In particolare, la presenza di β-HPV è stata riportata nei pazienti affetti da un raro 
difetto dell’immunità cellulo-mediata, chiamato epidermodisplasia verruciformis 
(EV), che causa un’elevata suscettibilità allo sviluppo del carcinoma a cellule 
squamose della pelle (SCC). Questo costituisce la prova iniziale secondo la quale 
gli agenti infettivi, come β-HPV, rappresenterebbero un potenziale fattore di rischio 
supplementare nello sviluppo dei tumori spinocellulari.  
Diversi studi hanno dimostrato le proprietà trasformanti delle oncoproteine virali, E6 
e E7, sia in modelli sperimentali in vitro che in vivo. Entrambe le proteine, alterando 
le funzioni di proteine cellulari, quali p53 e pRb, sono in grado di deregolare diversi 
eventi cellulari chiave, come il ciclo cellulare, la riparazione del danno del DNA, 
l'apoptosi e la senescenza.  
Sulla base di questi risultati in vitro, il nostro gruppo ha generato un modello 
animale di topi transgenici (Tg) che esprimono le proteine virali E6 e E7 di HPV38 
nello strato basale della pelle e nella mucosa epiteliale. Questi topi hanno mostrato 
un’elevata suscettibilità alla radiazione UV; infatti, la loro esposizione ai raggi UVB 
causa lo sviluppo di lesioni attiniche simili alla cheratosi che sono considerati come 
precursori del carcinoma a cellule squamose della pelle nell'uomo, e alcune 
settimane dopo hanno sviluppato il carcinoma conclamato. Al contrario, i topi wild-
type non hanno sviluppato alcun tipo di lesioni cutanee quando sono stati esposti 
alla stessa dose di radiazioni UV. Tuttavia, il meccanismo della cooperazione tra 
UV e HPV38 non è stato ancora chiarito e l’obiettivo di questo lavoro di tesi è stato 
quello di esaminare i meccanismi molecolari di tale sinergismo. 
A tale scopo, abbiamo valutato se l'espressione degli oncogeni virali negli animali 
transgenici potesse alterare l'espressione genica indotta dalle radiazioni UV. 
L'analisi dell'intero trascrittoma ha rilevato che più di 300 geni sono deregolati nei 
topi transgenici dopo l'esposizione ai raggi UVB, rispetto agli animali wild-type. In 
particolare, le oncoproteine E6 e E7 sono in grado di deregolare l'espressione di 
proteine coinvolte nella formazione dei complessi dell’inflammosoma o dei loro 
effettori a valle, come IL-18. È interessante notare che molti studi condotti su linee 
cellulari di cheratinociti hanno dimostrato che le radiazioni UV attivano 
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l’inflammosoma, portando alla secrezione di specifiche citochine pro-infiammatorie, 
come IL-1β e IL-18. 
I risultati ottenuti tramite RT-qPCR hanno confermato i dati dell’analisi del 
trascrittoma, mostrando che l'espressione dell’IL-18 è regolata nei topi wild-type 
dopo l'esposizione a UV, mentre è fortemente inibita nei topi transgenici. 
Successivamente, utilizzando i cheratinociti umani primari (HPKs) come modello 
sperimentale, abbiamo analizzato i meccanismi coinvolti nell'espressione dell’IL-18 
indotta dai raggi UV, nonché il ruolo di HPV38 nella deregolazione di questi eventi.  
I cheratinociti primari umani in seguito all’irradiazione con raggi UV mostravano un 
aumento dei livelli di espressione di mRNA dell’IL-18 e di altri componenti chiave 
dei complessi dell’inflammosoma, quali AIM2 e ASC; al contrario, la presenza delle 
proteine virali E6 e E7 riduceva fortemente l’espressione dell’IL-18 sia a livello di 
espressione di mRNA che di secrezione.  
L’utilizzo di cheratinociti esprimenti il gene della telomerasi umano (hTERT), al fine 
di prolungare il ciclo vitale delle cellule, quale modello sperimentale in vitro 
alternativo, ha messo in evidenza un elevalto livello basale di mRNA di IL-18 
rispetto ai cheratinociti primari; inoltre, la presenza di E6 e E7 svolge un ruolo 
inibitorio su tale espressione. 
L’espressione transiente di un vettore contenente il promotore isolato dell’IL-18 
clonato davanti al gene reporter della luciferasi, in cheratinociti esprimenti il gene 
hTERT, ha confermato la capacità di E6 e E7 di HPV38 di reprimere l'attività del 
promotore dell’Interleuchina 18. 
Inoltre, l'analisi del promotore dell’ IL-18, mediante l’utilizzo del programma 
bioinformatico TFBIND, ha rivelato la presenza di 15 putativi siti di legame per p53, 
classicamente attivato dalle radiazioni UV. Eseguendo test di 
immunoprecipitazione della cromatina (CHIP), abbiamo dimostrato che p53 viene 
reclutato in due distinte regioni del promotore dell’IL-18, che comprendono quattro 
elementi responsivi per p53. Le proteine E6 e E7 di HPV38 impediscono in modo 
efficace il reclutamento di p53 su queste regioni del promotore dell’IL-18.  
Questi risultati corroborano la nostra ipotesi circa la possibilità che β-HPV38 svolga 
un ruolo importante nell'inibizione della risposta dell’inflammosoma indotta dai 
raggi UV; in particolare, il virus potrebbe alterare l'espressione genica e la 
produzione di proteine coinvolte nella formazione del complesso 
dell’inflammosoma così come di citochine specifiche (quali ad esempio IL-18). 
Altresì, la riduzione della regolazione dell’IL-18 potrebbe compromettere la 
capacità dei cheratinociti di reclutare le cellule del sistema immunitario nell'area 
esposta ai raggi UV, causando un difetto nell'eliminazione delle cellule che hanno 
subito un danno al DNA.  
In conclusione, tutte queste alterazioni potrebbero determinare l'accumulo di danni 
al DNA indotti dall’esposizione ai raggi UV e allo sviluppo del cancro a cellule 
squamose della pelle.  
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Abstract 
Non-melanoma skin cancers (NMSC) are the most common human malignancies 
occurring in fair-skinned adult population, representing approximately 30% of total 
cancer. The etiology of this cancer is multifactorial, since genotypic, phenotypic 
and/or environmental factors can be involved in its development. 
Several studies have reported that the exposure to ultraviolet irradiation (UVB) 
represents a key risk factor in the development of skin cancer. Furthermore, 
infectious agents could be an additional risk factor and this hypothesis is supported 
by the evidence that immunocompromised people, e.g. organ transplant recipients 
(OTRs), show a higher risk of developing NMSC compared with immunocompetent 
individuals. Several infectious agents are able to colonize the skin and especially a 
subgroup of beta cutaneous human papillomavirus (HPV) is considered the most 
likely additional etiological factors of NMSC. 
In particular, the presence of β-HPV has been reported in patients with a rare cell-
mediated immunity disorder, called epidermodysplasia verruciformis (EV), which 
causes high rates of susceptibility to develop skin squamous cell carcinoma (SCC) 
on sun-exposed areas. Thus, it provided the initial clues about infectious agents, 
such as β HPV, as potential additional risk factor for NMSC. 
Several studies have demonstrated the transforming properties of the viral 
oncoproteins, E6 and E7, in in vitro and in vivo experimental models. Both proteins, 
altering the functions of tumour suppressor gene products, e.g. p53 and 
retinoblastoma (pRb), are able to deregulate key cellular events, such as cell cycle, 
DNA repair, apoptosis and senescence. 
Based on these in vitro results, our group has generated a transgenic (Tg) mouse 
model that express E6 and E7 oncogenes from beta HPV38 in the basal level of 
the skin and mucosal epithelia. Those mice were highly susceptible to UV-
radiation; in fact, the exposure of HPV38 E6/E7 Tg mice to UVB caused the 
development of actinic keratosis-like lesions that are considered as precursors of 
SCC in humans and a few week later SCC. Conversely, the wild-type mice did not 
develop any type of skin lesions when exposed to the same dose of UV radiations. 
However, the mechanism of the UV/HPV38 cooperation has not been elucidated 
yet. The aim of this work thesis was to dissect the molecular mechanisms of such 
cooperation. 
We have first determined whether the expression of the viral oncogenes in the Tg 
animals alters the pattern of gene expression induced by UV radiation. The 
analysis of the entire transcriptome pointed out that more than 300 genes are 
deregulated in the Tg mice after UVB exposure, compared to the wild type animals. 
In particular, the HPV38 E6 and E7 oncoproteins were able to down regulate the 
expression of proteins involved in the inflammasome complexes or the downstream 
effectors, such as IL-18. Interestingly, many studies in keratinocyte cell lines 
provided evidence that UV radiation activate the inflammasome pathway, leading 
the secretion of specific pro-inflammatory cytokines, like IL-1β and IL-18. 
RT-qPCR experiments confirmed the transcriptome findings, showing that IL-18 
expression is up-regulated in wild-type mice after UV exposure, while it is strongly 
inhibited in HPV38 E6/E7 Tg mice. 
Using primary human keratinocytes (HPKs) as experimental models, we dissected 
the mechanisms involved in the UV-induced IL-18 expression as well as the role of 
HPV38 in the deregulation of these events. RT-qPCR analysis showed an UV-
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induced upregulation of IL-18 mRNA expression as well as some key 
inflammasome components, like AIM2 and ASC, in HPKs cells; conversely, the 
presence of E6 and E7 oncoproteins strongly down regulated IL-18 both at the 
expression and secretion levels. Using another in vitro experimental model, such 
as keratinocytes expressing the human telomerase reverse transcriptase gene 
(hTERT), in order to prolong the life span of the cells, we found that this cell line 
presents a higher basal level of IL-18 compared to HPKs and the presence of E6 
and E7 plays an inhibitory role. 
Transient transfection experiments in hTERT HPKs using a vector containing the 
isolated IL-18 promoter cloned in front the luciferase reporter gene confirmed the 
ability of HPV38 E6 and E7 to repress the IL-18 promoter activity. 
The analysis of IL-18 promoter by TFBIND bioinformatics tool revealed the 
presence of 15 putative binding sites for p53, which is well known to be activated 
by UV radiation. Performing chromatin immunoprecipitation assays (CHIP), we 
showed that p53 is recruited to two distinct regions of the IL-18 promoters that 
includes four p53 responsive elements. Importantly, HPV38 E6 and E7 efficiently 
prevent p53 recruitment to these IL-18 promoter regions. 
Together these results corroborated our hypothesis that beta HPV38 play an 
important role in the inhibition UV-induce inflammasome response, by altering the 
gene expression and the production of proteins involved in the inflammasome 
pathways as well as of specific cytokines (e.g. IL-18). Most likely, the down 
regulation of IL-18 may impair the ability of the keratinocytes to recruit the immune 
cell population at the UV-exposed area, causing a defect in the elimination of cells 
harboring DNA damage. In conclusion, all these alterations may lead to the 
accumulation of UV-induced DNA damage and development of non-melanoma skin 
cancer.
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1. GENERAL INTRODUCTION 
Non-melanoma skin cancers (NMSCs) are the most common malignancies 
occurring in fair-skinned adult population, representing approximately 30% 
of total cancer [1], and their increased incidence has generated a great 
interest in the last few years, into understanding their pathogenesis in order 
to find new non-invasive treatments [2]–[4]. NMSC is  also known as 
keratinocytes carcinoma and is mainly used to describe basal-cell (BCC) 
and squamous cell carcinomas (SCC), although their aetiopathogenesis 
and clinical course are different [5]. BCC is considered a hair follicle-
derived tumor and is caused by few genetic alterations [6], while the 
development of SCC is caused by multiple factors and little is known about 
the causal alteration [7].  
 
The etiology of this cancer is multifactorial, in fact immune suppression, 
genetic and environmental factors are strong risk factors for NMSC 
development. In particular, several studies have reported that the exposure 
to ultraviolet irradiation (UVB) represents a key risk factor in the increase in 
incidence of skin cancer [8]. Furthermore, infectious agents could be an 
additional risk factor for skin cancer. This hypothesis is supported by 
evidence that immunocompromised people, e.g. organ transplant recipients 
(OTRs), show a higher risk of developing NMSC compared with 
immunocompetent individuals [9].  
 
The present work thesis will provide important insights into the molecular 
mechanism of the cooperation between two environmental, such as UV 
irradiation and HPV infection, in promoting skin carcinogenesis by the 
modulation of inflammasome response. To better understand the 
relationship between virus/NMSC/immune system responses, the 
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introduction is divided in 4 major parts that will provide a brief summary of 
current knowledge about these topics: 
- Pathogenesis of NMSC 
- Role of viruses in carcinogenesis, focusing on HPV infection and in 
particular on the β-type 
- Innate immune response to viral infection, with specific reference to 
inflammasome pathway activation and IL-18 production 
- Role of the immune system in cancer 
1.1  Pathogenesis of non-melanoma skin cancer 
Epidemiological data have reported that several factors (Table 1) and 
different pathways (Figure 1) could be involved in the pathogenesis of non-
melanoma skin cancers.  
Many studies show that NMSC occurs mainly on area of the body that are 
exposed to the sun and that the incidence in the development of skin 
cancer is associated with ambient solar irradiance. All this evidence 
provides further clues on the relation between this type of cancer and sun 
exposure [10]. Exposure to UVB radiation causes direct damage of DNA 
and RNA because it induces a covalent bond between adjacent pyrimidines 
with the formation [11]–[13] of cyclopyrimidine dimers (TT) or pyrimidine-
pyrimidine (6-4) adducts, that are mutagenic. Furthermore, UVA is less 
mutagenic compared to UVB because the DNA damage is indirect and is 
caused by the generation of reactive oxygen species (ROS). To prevent the 
harmful effects of these premutagenic adducts, the cells need an efficient 
DNA repair system.  
 
As mentioned above, another key risk factor for skin cancers is the 
immunosuppression. Literature data highlights that organ transplant 
      
10 
 
recipients, HIV-positive patients and with non-Hodgkin lymphoma patients  
have an elevated risk of developing NMSC in comparison to healthy 
individuals [14], [15]. The importance of the status of the immune system in 
skin carcinogenesis supports the possibility that an infectious agent is 
involved in this pathological condition. Many biological and epidemiological 
studies provide evidence that cutaneous β-HPV types can synergize with 
UV in promoting skin carcinogenesis. β-HPV types were first identified in 
patients with a rare cell-mediated immunity disorder, called 
epidermodysplasia verruciformis (EV). EV patients are highly susceptible to 
beta HPV infection and NMSC development in anatomical sites exposed to 
UV light. This finding provided the initial clues about infectious agents, such 
as β-HPV, as a potential additional risk factor for NMSC [16]. Furthermore, 
analysis of non-melanoma skin cancers in immunocompromised and 
immunocompetent individuals showed that both contain DNA from 
cutaneous human papillomavirus, although with different percentages [17]. 
How these viruses cooperate with UV irradiation in the development of skin 
cancer is not completely understood. One plausible hypothesis is  that β-
HPV, hampering the elimination of UV-damaged cells [18].  
Other risk factors for NMSC include TYR and ASIP gene variants and of 
the melanocortin-1 receptor (MCR1) as well as the inactivation of the TP53 
tumor suppressor gene by UV irradiation or the inactivation of CDKN2A 
locus.  
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Table 1: Environmental risk factors for non-melanoma skin cancer. Image 
from [5]. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Major pathways involved in the pathogenesis of non-melanoma 
skin cancer. Image from [5]. 
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1.2 Human cancers and viruses 
In 1911, Peyton Rous described that a filterable agent in cell extracts of a 
chicken tumor could transmit the tumor into healthy chickens [19]. This 
discovery paved the way into the study of tumor virology.   
Several decades later, two tumor viruses were discovered in mammals, 
suggesting that viruses may be risk factors in the development of some 
human cancers [20]. To date, approximately half of all human cancers are 
caused by infectious agents [21]. 
In 2009, the International Agency for Research on Cancer (IARC) 
Monographs program reviewed all the known infectious agents that have 
been classified as carcinogenic to human [22]. These viruses include HBV, 
HCV, HPV, EBV, KSHV (also known as human herpes virus type 8, HHV-8) 
and HTLV-1 (table 2).  
 
Viruses can be classified as direct or indirect carcinogens. The former can 
express oncogenes that play a direct role in cellular transformation by the 
alteration of key cellular pathways. In contrast, viruses classified as indirect 
carcinogens cause chronic inflammation in the infected area, leading to the 
dysregulation of immune system responses as well as to the promotion of 
angiogenesis, that is important for tumor development and survival. KSHV, 
HTLV-1, EBV and several HPV types belong to the first group, while HBV 
and HCV to the second. 
 
A vast number of studies have clearly demonstrated that viral oncoproteins 
display transforming activities in in vitro and in vivo experimental models. In 
EBV, LMP-1 induces the invasiveness and the production of metastasis 
factors, nuclear antigen 1 (EBNA-1) is able to bind DNA of the host 
regulating the transcription of cellular genes [23], and EBNA-2 plays a 
critical role in lymphocyte immortalization [24]. 
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KSHV express a protein called latency-associated nuclear antigen (LANA) 
which is able to dysregulate several pathways linked to cellular proliferation 
[25].  
HBV encodes HBx protein and hepatitis B surface antigen (HBsAg) that are 
important in transformation. Furthermore, integration of HBV genome 
causes disruption of key cellular gene that are involved in the regulation of 
proliferation [26]. 
 
 
Table 2: Human cancers viruses and their relative oncoproteins and 
cellular targets. Image modified from [21]. 
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2. HUMAN PAPILLOMAVIRUSES 
2.1 Classification  
The papillomaviruses are small DNA viruses that cause warts (or 
papillomas) in several higher vertebrates, including humans. The first 
papillomavirus was studied by Richard Shope in 1933, who described 
CRPV (cottontail rabbit papillomavirus) as the etiologic agent responsible 
for the cutaneous papillomatosis in cottontail rabbit. 
Historically, the papillomaviruses were grouped together with the 
polyomavirus in the papovavirus family because they shared similar 
properties such as small size, an icosahedral capsid and double-stranded 
circular DNA. However, further studies have highlighted differences in the 
genomic organization between papillomaviruses and polyomaviruses, 
which led to their reclassification as different virus family. 
PaVe: Papillomavirus Episteme report more than 300 papillomavirus 
identified and completely sequenced, of which 200 are human. 
Papillomaviruses classification is based on the DNA sequence of the L1 
gene. To be considered as a new PV type the L1 nucleotide sequence 
must differ by >10% of the closest known type. Differences between 2% 
and 10% define a subtype and less than 2% a variant. 
According with the phylogenetic tree (Figure 2), human papillomaviruses 
(HPVs) are divided in five genera identified with a Greek letter followed by a 
number that indicates the species. To date, the majority of HPV types are 
comprised in alpha, beta and gamma genera and are further subdivided 
into cutaneous or mucosal according to their tissue tropism. Genus alpha 
includes the mucosal HPV types that are sub-divided in high-risk (HR) and 
low-risk (LR) according to their ability to induce benign or malignant lesions. 
HR HPVs type are normally associated with development of cancer lesions, 
while the LR HPVs are linked with benign warts.  
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The genus beta includes several types of HPV that can be found on skin, 
which is why they are considered cutaneous type. The cutaneous types 
were isolated from patients with Epidermodysplasia verruciformis (EV), a 
rare autosomal recessive genetic disorder, and are also detected in non-
melanoma skin cancers of EV patients [27]. Epidermodysplasia 
verruciformis causes a decrease in the cell-mediated immune response 
making patients more susceptible to HPV infection. This provides evidence 
about the role of HPV infection in the pathogenesis of skin cancer 
associated with EV [28]. Moreover, recent studies have suggested the 
involvement of cutaneous β-HPV type in the development of skin cancer in 
non-EV patients. For instance, β-type are frequently detected in 
immunocompromised patients, such as organ transplant recipients (OTRs) 
or HIV infected people, as well as in NMSC of both immunocompromised 
and immunocompetent individuals [27], [29].  
The characteristics and the pathogenesis of β-type are described more in 
detail below. 
Genus gamma includes more HPV types than the other genera [30]. 
Interestingly, three gamma HPV types, 101, 103, and 108, isolated from 
cervico-vaginal cells of healthy women or women with cervical lesions 
revealed an unusual genome organization [31], [32]. All three genomes lack 
the E6 open reading frame (ORF). 
Currently, little is known about the biological properties of the gamma HPV 
types that can be found in high abundance on the skin of normal individuals 
[33]. 
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Figure 2: HPV phylogenetic tree. Alpha-, Beta- (blue) and Gamma-
papillomavirus represent the largest groups. Alpha papillomavirus genus 
includes low-risk cutaneous (light brown), low-risk mucosal (yellow) and 
high-risk (pink). The high risk highlighted in red are confirmed as “human 
carcinogens” based on epidemiological data. The evolutionary tree is based 
on the alignment of the E1, E2, L1 and L2 genes. Image modified  from 
[33]. 
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2.2 Structure of the virion and genome organization  
All HPVs are non-enveloped DNA viruses with an icosahedral structure, 50-
60 nm diameter. The capsid contains 360 molecules of L1 protein arranged 
into 72 capsomeres.  Each capsomer is composed of 5 L1 protein [32] that 
interact at the C-terminal [34]. The virion contains several L2 protein that 
are not fully exposed on the surface except for the N-terminal. During 
infection, L2 becomes exposed in order to bind the extracellular matrix [35]. 
Each virion contains a single copy of the genome, comprised of a double-
stranded, circular DNA of around 7,5-8 kb in length. One of the two strands 
contain the Open Reading Frames (ORFs) which encode for the viral 
proteins. The genome can be divided into three major regions: an  early, a 
late and a long non coding region (LCR or non-coding region, NCR), all of 
which are separated by two polyadenilated (pA)  sites, that are called early 
pA (AE) and late pA (AL) sites (Figure 3).  The LCR region, that represent 
around 10% of the genome, contains the origin of replication and the 
regulatory elements of the transcription [36]. 
Despite of the small size of the HPV genome, the number of encoded 
proteins is higher. This is due to the use of multiple promoters and complex 
patterns of splicing [37]. 
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Figure 3: The genome organization of HPV16. The viral genes are 
transcribed in a single direction (clockwise). There are genes coding for 
non-structural proteins (E1, E2, E4, E5, E6, and E7) and structural proteins 
(L1, L2), and a transcriptional control region (long control region; LCR). 
LCR contains a DNA replication origin and functions as the regulator for the 
DNA replication. The major promoters and polyadenylation signals are 
indicated (P97, P670, AE, AL). Image from [38]. 
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The early region occupies about 50% of the entire genome and contains six 
common ORFs that encode viral proteins involved in DNA replication, 
control of viral transcription and in pathogenesis: 
 E1 is highly conserved protein comprised of around 600 aa. It is a 
virus-specific DNA helicase that is involved in viral genome 
replication and amplification. 
 E2 is involved in viral transcription, replication and genome 
partitioning. It is conserved among the HPVs types in its N-term and 
C-terminal domains. 
 E4 is a small cytoplasmic protein that is involved in the remodeling 
of the cytokeratin, in cell cycle arrest and in virion assembly [39]. 
 E5 controls cell growth and differentiation, and it is also involved in 
the modulation of the immune system. Interestingly, Beta HPVs type 
lack of E5 ORFs. 
 E6 and E7 are the most studied and characterized proteins because 
of their role in oncogenesis. Their functions are described in more 
detail below. 
The late region encodes for the protein that form the capsid of the virion 
particles, L1 (major capsid protein) and L2 (minor capsid protein) [40], [41].  
2.3 Life cycle 
HPV life cycle is tightly linked to the differentiation program of the host cells 
and the target of these viruses is the stratified epithelium (Figure 4). The life 
cycle can be divided in two stages:  
- non-productive that occurs in the proliferating basal layers of the 
epithelium where the virus is present as a low copy-number 
episome 
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- productive that occurs in the terminally differentiated cells. 
Human papillomavirus virions invade the epithelium through damaged 
areas in order to infect the basal cells. The entry of the virions has not yet 
been fully characterized. The virion attaches to heparan sulfate 
proteoglycan (HSPG) on the basal membrane trough the major capsid 
protein, L1, and then transfers to the receptor expressed on keratinocytes 
moving on the basal membrane in the wound-healing process [35]. After 
the entry, the genome of the virus is transported into the nucleus where it is 
maintained in low-copy number (50-100 copies per cell). This step is 
essential for the establishment of the early phase of HPV life cycle (Figure 
4). After this, the infected cells start the differentiation program. HPV does 
not encode for any DNA polymerase enzyme so the virus needs the DNA 
replication machinery of the host. Viral gene expression is strictly related to 
the differentiation stage of the infected cells. Expression of the viral gene 
required for viral genome expression occurs in the spinous layer of the 
stratified epithelium and can be found at high-copy per cell. The capsid 
proteins are synthetized and assembled to form the virions in the 
differentiated cells. Then the new progeny is released with peeled 
keratinocytes [38]. 
  
      
21 
 
 
 
 
Figure 4: The lifecycle of human papillomaviruses (HPVs). HPVs 
specifically infect the cells in the basal layer of the stratified epithelium 
through lesions. Viral genomes are maintained as episomal DNA in the 
nuclei of infected cells. The viral lifecycle is strictly controlled by host cell 
differentiation, and the late lifecycle (productive lifecycle) occurs in upper 
layers of the epithelia that are terminally differentiated. The progenitor 
virions are released from the cornified keratinocytes. Image from [38]. 
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2.4 Oncogenic properties of E6 and E7 
The oncoproteins E6 and E7, encoded by human papillomaviruses, are 
directly responsible for the development of HPV-related cancer. They 
interact together by targeting different cellular pathways involved in 
regulation of cell cycle and apoptosis, in order to alter the host cell 
response. Unless otherwise stated, the description of the two viral 
oncoproteins refers to High Risk (HR) HPV, such as HPV16.  Due to their 
importance in cellular immortalization and transformation, E6 and E7 are 
considered the bests target to develop new therapeutic and antiviral 
strategies.  
2.4.1 E6 
E6 is a small nuclear protein of about 16-19 kDa with two zinc finger 
domains formed by two pairs of CXXC motifs, that are conserved among 
the human papillomaviruses and their integrity is essential for the protein 
functions (Figure 5) [42], [43]. The most characterized target of E6 is the 
tumor suppressor protein, p53.  
The main function of p53 is to arrange the response to cellular stresses 
leading to different outcomes, such as cell-cycle arrest, DNA repair or 
apoptosis. Under stress condition, p53 is rapidly stabilized by post-
translational modifications and regulates the expression of different cellular 
genes in order to preserve genome integrity. During HPV infection p53 is 
inactivated and degraded via the  proteasome pathway [44], [45].  
E6 from HR HPV types interacts with the unbiquitin ligase E6AP inducing a 
conformational change that generates a cleft for p53 binding. The formation 
of this trimeric complex, E6/E6AP/p53, leads to the rapid degradation of 
p53 [46].  
E6 from HR types inhibit the expression of p53-regulated genes through the 
interaction with CBP and p300, two histone acetyltransferases [47], [48].   
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E6 targets many other cellular pro-apoptotic proteins and one of the most 
studied is Bak. This protein could play a role in terminal differentiation 
because it is highly expressed in the upper part of the epithelium. 
Interestingly it has been described that after UV exposure, Bak is activated 
and stabilized independently of p53, in fact E6 binds Bak in order to 
degrade it via E6AP-dependent proteasome [44]–[47].  
 
The viral oncoprotein interacts with other components of the apoptotic 
pathway. It acts indirectly by upregulating the activity of survivin promoter in 
order to block apoptosis [53]. HPV E6 also interacts with the tumor necrosis 
factor receptor 1 (TNF R1), the adaptor molecule Fas-associated death 
domain (FADD) and pro-caspase 8. The interaction between E6 and FADD 
or pro-caspase 8 mediates the degradation of both proteins [49]–[51]. 
E6 is also able to deregulate the cellular DNA replication machinery. It 
prolongs the life-span of the primary epithelial cells by increasing the 
telomerase activity, through the activation of the transcription of the human 
telomerase reverse transcriptase (hTERT) gene [57], [58]. This activation is 
in part due to E6/E6AP complex that causes the binding and the 
degradation of NFX1, a negative transcriptional regulator. 
Moreover, other studies have shown that the hTERT activation requires the 
binding of E6 to Myc, but not to E6AP, which in turn is able to activate 
hTERT promoter [54]–[56]. 
However, to date the exact mechanism of hTERT gene activation is not 
fully clear although this event appears to be crucial for HPV-induced 
immortalization and transformation.  
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Figure 5: Schematic diagram of the high-risk HPV E6. The two zinc 
fingers are shown, together with regions that are involved in interacting with 
some of its cellular target proteins. The C-terminal PBM is shown and the 
PKA phosphorylation site is also indicated. Image from [62]. 
2.4.2 E7 
E7 is protein of 10-14 kDa with a C-terminal zinc-binding domain and 
structural integrity is important for E7 activity [63], [64]. The viral 
oncoprotein protein is divided in three conserved domains, identified as 
CD1, CD2 and CD3 (Figure 6).  
The ability of E7 to induce S-phase progression and cellular transformation 
is dependent on the CD1 domain [64], [65].  
The CD2 domain contains a LXCXE motif that mediates the interaction with 
the retinoblastoma tumor suppressor protein (pRb). In many E7 proteins, 
this domain also contains a phosphorylation site of casein kinase 2 (CK2). 
Lastly is the CD3 domain, which contains four highly conserved cysteine 
residues and is involved in interaction with different cellular proteins, such 
as p21 and p27 CDK inhibitors. E7 abrogates the activity of those proteins 
in order to permit the cell cycle progression and overcoming the cell cycle 
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arrest due to DNA-damage [67], [68]. It can also interact with several 
transcription factors like AP-1(activator protein 1), TBP (TATA box binding 
protein) or c-Jun [69].One of the most studied properties of E7 is its ability 
to target pRb, p107 and p130. pRb plays a key role in cell-cycle control; in 
particular, it negatively regulates the G1/S transition. pRb, via direct 
binding, inhibits the activity of the transcription factors E2F1–3, which are 
involved in the expression of many genes encoding positive cell-cycle 
regulators, such as cyclin E and A. In normal cells, cell-cycle progression is 
dependent on the formation and activation of the cyclin D1-3/cyclin-
dependent kinase (CDK) 4 and 6 complexes, which in turn phosphorylate 
pRb. pRb hyperphosphorylation leads to the release of E2F1–3, which are 
active in promoting cell-cycle progression. HR HPV E7 proteins associate 
with hypophosphorylated pRb, mimicking the CDK-mediated 
phosphorylation and resulting in uncontrolled and constitutive activation of 
E2Fs. Similar to E6 with p53, HPV16 E7 protein is able to promote pRb 
degradation through the ubiquitin-proteasome pathway. Thus, HR HPV E7-
expressing cells undergo unscheduled proliferation, which is independent 
of external stimuli. 
 
E7 also binds other cellular proteins, such as p107 and p130, whose play a 
role in regulation of cellular proliferation, differentiation and apoptosis [70]. 
In particular, p107 is expressed in proliferating cells and inhibits E2F4, 
while p130 is present in non-proliferative cells and inhibits E2F5 activity 
[71], [72].  
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Figure 6: Schematic diagram of the high-risk HPV E7. Three regions of 
E7 that are homologous to adenovirus E1A conserved regions 1-3 (CD1-3) 
are shown. The zinc finger is also shown, together with the regions involved 
in pRb binding (LXCXE) and the two serine residues (31 and 32) that are 
susceptible to casein kinase II (CKII) phosphorylation. Image from [62]. 
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2.5 Mucosal human papillomavirus infections 
The association between HPV and cervical cancer is well known. 
Epidemiological studies reported that the detection of HPV increases with 
the disease severity with percentage of 50-70 % in CIN1/LSIL, 85% in CIN2 
and around 90-100% in CIN3 lesions [73]–[75]. These viruses are sexually 
transmitted and their detection is higher in young women and men [76]. 
Twelve HR HPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58 and 59) 
are associated with the development of cancer in humans in different 
genital tracts, such as anal, vulvar, penile, vaginal and the well-known 
cervical tract. Among the HR HPV types, HPV16 and 18 are the most 
oncogenic viruses responsible for approximately 70% of all cervical 
squamous cell carcinomas (CSS) and adenocarcinomas (ADC). The 
immune system is able to clear the infection of HR HPV types in 12-14 
months without clinical manifestation but in some cases the infection may 
persist and after a period of latency, can evolve into premalignant lesions 
which can lead to the development of invasive cervical carcinoma. 
Recent studies have also demonstrated the association of HR HPV in a 
subset of head-and-neck cancers (HNSCC). Most of the HNSCCs positive 
for HPV are in the oropharynx, but a small percentage, 1-2, of oral and 
laryngeal cancers have been attributed to HPV infection. The percentage of 
HR HPV-positive oropharyngeal cancers varies according to geographical 
regions, ranging from approximately 10% in East European countries to 
50% in north European countries and North America. In the oropharyngeal 
cavity there are the tonsillar crypts that are formed by a specialized 
squamous epithelium, which is infiltrated with lymphoid tissue. The 
susceptibility of this body site to HPV infection is probably due to the 
presence of “basaloid” cells, which permit virus entry, and could also be 
due to the special conformation of the crypts that are considered “immune-
privileged zones” facilitating the virus immune evasion [77]. Epidemiological 
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analysis show that in these areas the HPV-related cancers are principally 
HPV-16 positive, with a low percentage of other HR-HPV types, such as 
HPV-18, HPV-31 and HPV-32 [78]–[81]. 
As regards the LR HPV types, they are responsible for genital warts or 
condylomata acuminate and the infections are cleared by the immune 
system within 2 years. Recurrence of the infections, however, can be 
observed in a small percentage of cases. HPV-6 and 11 are also 
associated with the rare laryngeal papillomatosis in children as well as in 
adults and the infection is acquired during the passage through an HPV-
infected birth canal. Although , these tumors do not usually progress to 
malignancy [82] 
2.6 Cutaneous human papillomavirus infections 
The HPV types associated with cutaneous diseases belong to different 
genera. The most common are the alpha types HPV-2, 3, 10, 27 and 57, 
the gamma type HPV-4, 60 and 65, and the mu types HPV-1 and 63. 
These are normally present in common warts that can occur at many sites, 
such as the feet and hands. In most cases, these are benign lesions with a 
spontaneous immune regression of 80%, but they are highly productive 
with a number of particles around 1012. The common warts generally show 
hypertrophy that leads to acanthosis or thickening of the epithelium. The 
transmission of the virions released from the infected epithelium can occur 
indirectly or directly from person to person [82]–[84].  
Molecular analyses have also shown the presence of certain human 
papillomaviruses belonging to the β-genus, such as HPV-8, HPV-20 and 
HPV-38, in cutaneous epithelia. 
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2.7 β-HPV infections of cutaneous epithelia 
Approximately 50 different β-HPV types have been characterized so far, but 
it is likely that many more exist. The first characterized β-HPV types, HPV-5 
and 8, were isolated in the skin of individuals suffering from 
epidermodysplasia verruciformis (EV), as described above. Since the 
discovery of HPV-5 and 8, many more beta HPV types have been isolated, 
as a result of the development of highly sensitive polymerase chain 
reaction (PCR)-based methods [30]. They are subdivided into five different 
species: beta-1, -2, -3, -4, and -5 and can be detected on the skin, oral 
cavity and also in genitals area of healthy people, in fact the environment of 
β-types infection is significantly different from the one where the HR α-types 
infect the host cells. Commonly, they can be found in proximity to the hair 
follicles, nails, between the digits and also at the eccrine and apocrine 
sweat apparatus; the characteristic of these different district is the presence 
of different tissue close to each other. For example, the sweat glands 
present two different stem cells population both of which susceptible to the 
virus infection. It seems that the virus is able to reach the cells of these 
areas via hair follicles, via micro-injuries or via the eccrine ducts, depending 
on the zone [33]. 
However, biological and epidemiological studies support the role of  β-HPV 
type in the development of non-melanoma skin cancer (NMSC), together 
with ultraviolet (UV) light [86]. For instance, it has been reported that people 
with a history of skin SCC show a higher positivity for viral DNA in the skin 
and/or antibodies against the L1 major capsid protein [87]–[92]. Moreover, 
the DNA load of the virus is higher in actinic keratosis lesions, which are 
considered the premalignant lesions of SCC, than in SCC [93], [94] Thus, 
as reported at the beginning, these findings support the hypothesis that β-
HPV types play a role at early stages of carcinogenesis, facilitating the 
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accumulation of DNA damage induced by UV exposure, which is one of the 
most important risk factors for NMSC. 
2.7.1 The β E6 and E7 proteins 
The β-HPV E6 and E7 oncoproteins are able to interact with similar cellular 
proteins and relative pathways, as HR alpha-HPV oncoproteins, but 
functional studies have shown that there are some important differences 
between the two types. 
One of the most relevant difference is the way in which they target the 
tumor suppressor protein, p53. As previously mentioned, α-HPV E6 targets 
p53 for proteasome-mediated degradation while the majority of β-HPV E6 
proteins are not able to do this. Literature data shows that some β-types, 
such as HPV-49, target p53 for proteasome degradation via E6AP [95], 
while others, such as HPV-38 and HPV-92, bind p53 stabilizing the cellular 
protein [96]. The E6 proteins of β-types are also able to interfere with the 
expression of p53-related genes. Muench and colleagues reported that the 
E6 proteins of HPV-5, HPV-8 and HPV-38 interact with p300. In particular, 
HPV-8 E6 induces p300 degradation leading to the reduction of ATR 
protein levels, which is an important protein of the UV-induced damage 
signaling pathway [97]. The interaction between E6 and p300 blocks also 
p53 acetylation, causing the inhibition of its transcriptional functions [98]. 
Furthermore, HPV-23 E6 binds and inhibits HIPK2 kinase leading to the 
prevention  of UV-induced p53 phosphorylation at residue serine 46 [99].  
E6s of β-types also block p53-dependent and independent apoptosis, 
which is induced in cutaneous sites after UV exposure and DNA damage, 
similar to the α-HPV types [50]. They also inhibit and degrade the protein 
Bak via E6AP proteasome-mediated degradation; probably for this reason 
Bak protein levels are undetectable in HPV-positive cancers, compare to 
the ones HPV-negative [100]. Recently, Holloway and colleagues showed 
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that HPV-5 E6 protein requires HERC1 ubiquitin ligase for Bak degradation 
[101]. HPV-38 E6 also interacts with the ubiquitin ligase p600/UBR4 but the 
role of this interaction is still unclear [102].  
 
Literature data shows that β-type E6 proteins interact with many other 
cellular targets, such as MAML-1 and hTERT. MAML-1 is a transcriptional 
activator of Notch-regulated genes but the strong binding between this 
cellular protein and E6 leads to the inhibition of the Notch signaling 
pathway. It is known that Notch inhibition slows epithelial differentiation and 
this event could contribute to viral oncogenesis. The binding of MAML-1 
takes place at the LXXLL motif, which is the same motif used by the E6 
from α-HPV type to bind E6AP [96], [103], [104]. It is likely that the 
differences between α and β-HPV types in binding preferences represent 
an evolutionary adaptation to the different tissue where they replicate.  
 
Regarding hTERT, HPV-5, HPV-20, HPV-22 and HPV-38 activate it via 
E6AP, and the intensity of the telomerase activation depends on the 
strength of the bond between E6 and E6AP (Figure 7 and 8). In fact, E6 of 
HPV-38 binds E6AP strongly and in combination with E7 is able to 
immortalize human primary keratinocytes [105], [106]. 
The interactions between E7s of β-HPV types with cellular proteins have 
not been as well-characterized as those of α-type. They contain the LXCXE 
motif and interact with pRb, p107 and 130, but to date only E7 of HPV-38 is 
able to degrade pRb in rodent fibroblasts while in human keratinocytes E7 
phosphorylates the retinoblastoma protein inhibiting its function[42], [95], 
[105], [107].  
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Figure 7: Biological properties of beta HPV E7. Image from [108] 
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An additional role of HPV-38 E7 is to induce changes in the regulation of 
p53 related genes. It has been reported that in the skin of transgenic mice, 
E7 cooperates with E6 to induce p53 stabilization that leads to the 
transcription of ΔNp73α isoform of p73. The accumulation of ΔNp73α 
blocks the transcription of p53-related genes involved in the regulation of 
cell cycle and apoptosis. Furthermore, E7 directly regulates IKKβ nuclear 
translocation and promotes the formation of the complex 
ΔNp73α/IKKβ/DNMT1/EZH2. This complex binds different p5-related 
promoters in order to inhibit their activation. Finally, the immortalization of 
the keratinocytes mediated by E6 and E7 of HPV-38 is related to hTERT 
overexpression which, as previously mentioned, that in turn is partly due to 
ΔNp73α accumulation (Figure 7 and 8).  
 
To date, only HPV-8 and HPV-38 seem to promote tumorigenesis in 
transgenic mice [86], [112], [113]. The results obtained in mouse models 
show that when HPV-8 early region, HPV-8 E6 or HPV-38 E6/E7 are 
expressed from a K14 promoter epidermal hyperplasia forms and in some 
cases squamous cell carcinomas result. Furthermore, UV- exposure of 
these mice increases the numbers of squamous cell carcinoma while the 
wild mice do not develop any  such lesions [113].  
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Figure 8: Biological properties of beta HPV E6. Image from [108]. 
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3. INNATE IMMUNE RESPONSE TO VIRAL INFECTION 
Vertebrates have developed different mechanisms of defense towards viral 
infections. Immune cells of the host are able to recognize the invasion of 
the pathogens and activate strong antiviral responses. Two distinct parts, 
the innate and the acquired immune system, compose the immune 
response of mammals, which work together in order to eliminate the 
pathogens. Initially, the presence of the virus activates the innate immune 
response, while the components of the acquired immune system play an 
important role in the response to re-infection.  
The host recognizes specific viral components (pathogen-associated 
molecular patterns, or PAMPs), such as viral genomes or viral proteins, 
through pattern recognition receptors (PRRs) that are divided in three 
classes: Toll-like receptors (TLRs), retinoic acid-inducible gene I (RIG-I)-
like receptors (RLRs) and nucleotide oligomerization domain (NOD)-like 
receptors (NLRs) (Figure 9).  
Among them, the best characterized are the TLRs [114], [115]. They are a 
group of highly conserved integral membrane glycoproteins found 
throughout the evolution, from Drosophila to humans, and their discovery 
was an important event for immunology [116]. The mammalian TLRs family 
is composed of 13 members, which are activated by different evolutionary-
conserved molecular structures. They are expressed on different immune 
cells as well as on epithelial cells and fibroblasts [117]. The Toll-like 
receptors expressed on the cell surface recognize microbial membranes, 
whereas the TLRs expressed in intracellular compartments (such as TLR3, 
7, 8 and 9) recognize the viral genome.  
The RLRs are a family of cytoplasmatic proteins that include RIG-1, MDA5 
(melanoma differentiation-associated gene 5) and LGP2 (laboratory of 
genetics and philsiology-2), that recognize viral RNAs in the cytoplasm of 
the host cells [118], [119].  
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NLRs are soluble proteins that survey the cytoplasm in order to detect 
intracellular pathogens. The NLR family is composed by NODs, NALPs, 
IPAF (IL-1β-converting enzyme (ICE)-protease activating factor), NAIPs 
(neuronal apoptosis inhibitor factors) and MHC class II transactivator 
(CIITA) [120]. NOD1 and NOD2 are the first NLRs to have been described 
and they drive the activation of MAPK (mitogen-activated protein kinase) 
and NF-kB pathway [121]. The activation and oligomerization of NLRs 
proteins leads to the formation of multiprotein complexes called 
inflammasomes. The structure and the inflammasomes pathway will be 
described more in detail below. 
Evasion of the host immune system is important for viruses as it allows 
them to persist inside the cells and to produce new viral progeny. To do 
this, viruses have developed over time several strategies in order to 
modulate the innate immune system suppressing or escaping from the host 
defense and establish a productive infection. 
Lastly, an additional role of the PRRs is to recognize also endogenous 
danger by sensing danger-associated molecular patterns (DAMPs).  
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Figure 9: Innate immune sensors. TLRs, RLRs and NLRs are innate 
immune sensors that recognize danger signals derived from pathogens 
(PAMPs), damaged cells (DAMPs) or associated nucleic acids on the cell 
surface, in endolysosomes or in the cytoplasm. Signaling by these sensors 
promotes either the activation or nuclear translocation of transcription 
factors (IRFs, NFκB and AP-1) that drive expression of cytokines (IFN-α/β, 
TNF and pro-IL-1β), or the assembly of the caspase-1 inflammasome and 
subsequent maturation of IL-1β from pro-IL-1β.  Image from [122]. 
 
3.1 Inflammasome 
In 2002, Tschopp coined the term inflammasome to describe a high-
molecular-weight complex, present in the cytoplasm of immune cells, 
responsible of the activation of inflammatory caspases [123]. 
Inflammasomes have been recognized for their important role in host 
defense against microorganisms and their assembly is due to unique 
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PAMPs or DAMPs, but it has also been reported that dysregulation of 
inflammasome activation is linked to the development of cancer or to 
autoimmune, metabolic or neurodegenerative diseases [124]. Due to their 
role, a tight control of inflammasome assembly and signaling is necessary 
in order to initiate antimicrobial and inflammatory responses, and to avoid 
tissue damage.  
According to their structural components, inflammasome sensors are 
grouped into nucleotide-binding domain-like receptors (NLRs), absent in 
melanoma 2-like receptors (ALRs) and pyrin, which has been most recently 
identified. Most inflammasomes also use also an adaptor protein called 
ASC (apoptosis-associated speck-like protein containing a caspase 
activation and recruitment domain). Detection of the stimuli by the sensors 
leads to the aggregation of ASC to form specks inside cells, which in turn 
recruits caspase-1, inducing its autocatalytic cleavage. Finally, the active 
form of caspase-1 processes different cytokines, such as IL-1β or IL-18.  
Many other cellular signals are involved together with the inflammasome 
components in the defense against pathogens or cells damage.  
3.1.1 NLR family 
All the members of this family share the same structure: a central 
nucleotide-binding domain (NBD) with a C-terminal leucine-rich repeat 
(LRR) domain and a variable N-terminal domain, which may contain a pyrin 
or caspase activation and recruitment domain. Members of NLR family can 
be also subdivided into NLRP or NLRC depending of the N-terminal (Figure 
10). 
- NLRP1 
NLRP1 was the first sensor identified by its ability to form an inflammasome 
complex [123] and human cells present only one NLRP1 protein while in 
rodents it has been found several paralogues.  
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In humans, NLRP1 is composed of the following domains: an N-terminal 
PYD, an NOD, LRRs, FIIIND (function-to-find domain) and a C-terminal 
CARD. The specific regulatory mechanism of NLRP1 is still not very well 
described. Several studies have reported that mutations in this protein 
cause auto inflammatory diseases, such as vitiligo, Addison’s disease, 
rheumatoid arthritis, Crohn’s disease and systemic sclerosis . Moreover a 
recent study showed that NLRP1 is the most expressed inflammasome 
sensor in human skin and two Mendelian monogenic skin disorders, 
multiple self-healing palmoplantar carcinoma (MSPC) and familial keratosis 
lichenoides chronica (FKLC), are caused by distinct gain of function 
mutations in NLRP1 gene [128]. 
To date, nothing is known about microorganisms and NLPR1 activation in 
humans, while in mice it seems to be activated by a lethal toxin of Bacillus 
anthracis. Both rat NLRP1 and mice NLRP1b confer resistance to 
Toxoplasma gondii infection [129]. 
- NLRP3  
NLRP3 is the most studied inflammasome and its domain structure is PYD-
NACHT-LRRs (from N-terminal to C-terminal). When activated, NLRP3 
forms a homo-oligomer via NACHT domain and interacts directly with ASC, 
via the PYD domain. ASC interacts with its CARD domain with pro-
caspase-1 leading to the cleavage and the activation of caspase-1 [130]. 
NLRP3 is also known as cryopyrin because it was associated with 
hereditary auto inflammatory syndromes called cryopyrin-associated 
periodic syndromes, characterized by skin rushes and episode of fever 
[131]. It responds to different stimuli, both external and endogenous, and it 
is implicated in the pathogenesis of many auto inflammatory diseases, such 
as arthritis, diabetes, gout, obesity and Alzheimer’s disease [132]. Despite 
several years of studies, the mechanism of NLRP3 activation is still 
unclear; it requires priming by external stimuli, which leads in the 
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transcriptional induction and post-translational modification of this sensor. 
However, three mechanisms of activation have been proposed. The first 
involves the ion channels. The increase of extracellular concentration of 
ATP leads to the stimulation of potassium ion efflux, through P2X7 ATP-
gated ion channel, and the formation of membrane pannexin-1 pore. These 
events facilitate the influx of PAMPs and DAMPs [133]. The second 
mechanism involves the lysosomal rupture model and it is related to 
activators, such silica or asbestos aggregates, which enter cells via 
phagocytosis. This induces lysosome collapse and the release of lysosomal 
contents, such as cathespin B which leads to NLRP3 activation [134]. The 
last mechanism is related to reactive oxygen species (ROS) production 
where some stimuli induce the production of ROS by NADPH oxidase, 
which in turn activates NLRP3 [135], [136]. 
A different activation pathway has also been proposed for NLRP3 
inflammasome, known as the non-canonical activation pathway (Figure 11) 
to differentiate it from the “canonical” pathway of activation described 
above. It results in caspase 11 activation, in mice, or caspase 4 and 
caspase 5 in humans. When the lipopolysaccharide (LPS) reaches the 
cytosol, it is directly bound by caspase 11, 5 or 4. This binding leads to the 
oligomerization and activation of the caspases, which in turn cleaves 
gasdermin D to induce pyroptosis. Thus, the activation of caspase 11 
causes the non-canonical activation of NLRP3 inflammasome with the 
consequent activation of pro-caspase 1 and the cleavage and the release 
of pro-inflammatory cytokines [134]–[136]. 
How caspase 11, and more specifically human caspases 4 and 5, promote 
the non-canonical activation of NLRP3 needs to be better characterized.  
 
As described above, several PAMPs from pathogens can activate NLPR3 
and among them, the most common viral activator is influenza virus. 
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Infection by influenza virus induces caspase-1 cleavage and maturation 
[140]. It is likely that this activation occurs through the lysosomal rupture 
and ROS models [141], [142]. In addition, HCV also seems to activate 
NLRP3 through the ROS model, even if the detailed mechanism of action 
requires further study [143]. Many other viruses have been reported as 
NLRP3 activators, such as Herpes simplex 1, Vesicular stomatitis virus, 
West Nile virus and rabies virus. All of which are able to induce capsasi-1 
maturation and IL-1β secretion.  The exact mechanism of inflammasome 
activation, however, is still unclear.  
 
Finally, three recent reports have shown the potential role of NIMA-related 
kinase7 (NEK7), a protein known to be involved in cell cycle progression, 
during NLRP3 activation. According to these studies, NEK7 acts 
downstream of potassium efflux and is able to activate the inflammasome 
complex in response to both canonical and non-canonical stimuli. The 
authors of the reports also demonstrated the ability of NEK7 to bind NLRP3 
and controls its oligomerization, with NEK7 itself a component of the 
inflammasome complex. Because NEK7 plays a role in promoting mitotic 
spindle formation, when cells enter mitosis we assist to an attenuation of 
NLRP3 activation. This regulation is probably a safeguard cells employ to 
control inflammasomes during cell division, when there may be many 
endogenous ligands inside cell that could be misrepresented as cellular 
stress  [143]–[145]. 
- NLRC4 
Initially, NLRC4 was identified for its similarity to APAF-1 (apoptotic-
protease activating factor 1). NLRC4 contains a winged-helix domain and 
together with NBD its domain stabilizes, the inflammasome in a closed 
conformation under basal conditions. On the other hand, LRR domain acts 
as a steric hindrance preventing the oligomerization of the complex. These 
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two mechanisms are important to maintain NLRC4 in an inactive state in 
absence of a ligand [147]. Unlike other NLR family members, NLRC4 does 
not interact directly with its activators but instead requires proteins, called 
NAIPs (NLR family, apoptosis inhibitory proteins), which act as a sensors 
that recognize the ligand [148], [149]. In humans, only one gene has been 
found that encodes NAIP [150]. Several PAMPs can activate NLRC4, such 
as bacterial flagellin or Salmonella infection. The activation of the 
inflammasome complex leads to procaspase-1 activation, which is 
mediated by the CARD domain. Man and colleagues showed that in 
macrophages infected with Salmonella, NLRC4 induces an actin 
polymerization response and also increases the intracellular level of ROS in 
order to kill the intracellular pathogen and to avoid bacterial dissemination.  
Moreover, NLRC4 is also active in epithelial cell infected with Salmonella. 
This activation is important to control pathogen load and extra intestinal 
dissemination [151]. Finally, different human genetic studies have shown 
that autoinflammation and enterocolitis may be due to gain-of-function 
mutations in NLRC4 gene [152], [153]. Further studies are required to 
better elucidate the role and the mechanism of activation of this 
inflammasome complex in human patients.  
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Figure 10 The NLR inflammasomes. Image from [154] 
 
 
Figure 11: The canonical and non-canonical NLRP3 inflammasome 
activation. Image from [137]. 
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3.1.2 ALR family 
The expression of the members of this family is restricted to and conserved 
in mammals and the most well studied member is AIM2 (absent in 
melanoma 2) (Figure 12) [155]. All the members contain an N-terminal PYD 
domain and a C-terminal hematopoietic interferon-inducible nuclear protein 
with HIN200 (200-aa repeat) domain. The AIM2 PYD domain is different 
from other members of this family, in fact it is the only one able to interact 
with ASC to form an inflammasome complex. Another difference between 
AIM2 and other members of ALR family is the lack of the nuclear 
localization signal; which why AIM2 can be found only in the cytoplasm 
[156]. Kerur and colleagues showed that γ-INF-inducible protein 16, 
another human ALR, could be a putative inflammasome because of its 
ability to interact with the adaptor protein, ASC [157]. 
- AIM2 
Initially identified improperly as a γ-INF-inducible protein, AIM2 is a nucleic 
acid sensor able to form an inflammasome complex in response to double-
stranded DNA [157]–[159]. The recognition of the dsDNA is mediated by 
the HIN200 domain and is independent of sequence identity, although it 
does require around 80 bp of dsDNA [161]. Moreover, structural studies 
have revealed that HIN200 domain plays an auto inhibitory role because in 
absence of a ligand it interacts with the PYD domain to avoid homotypic 
interaction with ASC. In this complex, AIM2 and ASC form the center of the 
structure while caspase-1 constitutes the filaments [162] and has also been 
identified as a negative regulator of AIM2 inflammasome. It belongs to 
HIN200 family and it is known as p202. AIM2 lacks the PYD domain and 
most likely acts by sequestrating dsDNA and/or mediating AIM2 
heterodimerization [159], [163]. AIM2 is able to bind both bacterial and viral 
DNA but the signaling pathways for each are different. In fact, in response 
to bacterial stimuli type I IFN signaling is required to promote bacterial lysis 
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and the consequent release of the genome that is necessary for AIM2 
activation. The same pathway is not involved  during viral infection [164], 
[165]. Moreover, recent studies have shown that some bacteria, such as 
Mycobacterium or Legionella, produce several virulence factors that reduce 
the quantity of dsDNA release in order to evade AIM2 detection [165]–
[167].  
Finally, AIM2 can also detect host DNA released in response to cellular 
damage. This event occurs in various auto inflammatory diseases, such 
psoriasis or systemic lupus erythematosus. For this reason, AIM2 is 
considered as a possible therapeutic target for autoimmune disorders [169], 
[170].  
3.1.3 The pyrin inflammasome 
The gene MEFV encodes Pyrin, also known as marenostrin or TRIM20 
(Figure 12).  A PYD domain, two B-boxes and a coiled-coil domain 
compose this new inflammasome and only recently, its physiological 
function has been discovered. Pyrin is associated with an auto 
inflammatory disorder called familial Mediterranean fever and the 
inflammasome can be activated in response to bacterial toxins, such as 
Clostridium difficile protein B and Clostridium botulinum C3 toxin, or to 
effector proteins, likes VopS from Vibrio parahaemolitycus and IbpA from 
Histophilus somn [171]. Recently 14-3-3 proteins were identified as 
regulators of pyrin activity. When Pyrin is phosphorylated, under basal 
conditions, binds 14-3-3 proteins, while its dephosphorylation attenuates 
14-3-3 binding. Moreover, a human mutation in this phosphosite causes 
pyrin activation also in the absence of stimuli [172]. However, the exact 
mechanism of interaction between pyrin and 14-3-3 protein needs to be 
clarified.  
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Figure 12: The pyrin and AIM2 inflammasomes. Image from [154]. 
 
3.1.4 Other inflammasome complexes 
Several studies have shown that many other inflammasome complexes 
might yet exist. NLRP6 and IFI16 appear to be able to form multiprotein 
complexes with consequential maturation and release of pro-inflammatory 
cytokines.  
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It has been demonstrated that mice knock out for Nlrp6, Asc or Casp1 
show an invasive dysbiotic microbiota with an increased susceptibility to 
chemically induced colitis and colitis induced tumorigenesis [173]. These 
mice show also a deficiency in IL-18 secretion from intestinal cells but, how 
NLRP6 controls this event is still unclear.  
Regarding IFI16 and the mouse orthologue IFI204, they seem to play an 
interesting role as regulators of STING (stimulator of IFN genes)-dependent 
IFN production during infection [174], [175]. It has also reported that IFI16 
interacts with ASC in the nucleus of cells infected with KHSV, and that it 
mediates caspase 1 activation during HIV infection [157], [176], [177].  
Despite these studies, additional analysis are necessary to confirm 
unequivocally IFI16 as inflammasome.  
3.2 Inflammasome assembly and structure 
Inflammasome activation is a complex mechanism highly regulated that 
consists in three stages: stimulus, receptor activation and recruitment of the 
adaptor ASC and pro-caspase1. 
The structure of inflammasome complexes is object of several study. Cryo-
electron microscopy analysis demonstrated that its structure is similar to 
the apoptosome and it adopt a wheel- or disk-like architecture, with 10-12 
spokes that correspond to the individuals promoters [178], [179]. Moreover, 
during NLRC4 activation there is a conformational change due to a rotation 
of 90°. This is important to promote the progressive oligomerization of the 
complex [180], [181]. On the contrary, AIM2 shows a different complex 
formation because of the lack of a NOD domain that normally mediates 
self-oligomerization. In this case, cytosolic DNA is bound by HIN domain 
forming an oligomerization template or scaffold [161].  
After the assembly of the receptor complex, this structure recruits the 
adaptor ASC and also pro-caspase 1, through homotypic interactions PYD-
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PYD or and CARD-CARD. When recruited, ASC forms a single 
macromolecular aggregate called ASC speck, which are composed by 
filaments of ASC [162], [182]. These filaments act as a recruitment point for 
pro-caspase 1. Even if ASC is essential for this signal, sometimes also 
CARD-containing receptors could directly recruit and activate pro-caspase 
1. However, the lack of ASC leads to a reduction of IL-1 β release, in mice 
Asc-/-. This indicates that the maturation and release of this cytokine is 
closely linked to ASC speck formation. This result is supported by evidence 
that single point mutation in ASC gene abrogates the ability of 
oligomerization of this adaptor protein, leading to a reduction of speck 
formation, pro-caspase processing and IL-1 β maturation after 
inflammasome activation.  
Thus, ASC is important and acts as a signal amplification mechanism for 
inflammasome-mediated cytokines production.   
3.3 Inflammasome effector mechanisms  
Several study in mouse model have highlighted two important 
inflammasome effector mechanisms: pyroptosis and cytokine release. 
The term pyroptosis refers to the pro-inflammatory cell death induced by 
inflammatory caspases, such as caspase 1 in humans and caspase 11 in 
mice. The term comes from the Greek “pyro”, that means fire, and “ptosis”, 
that means fall [183]. Pyroptosis is a particular kind of cell death 
characterized by cell swelling, lysis and release of cytoplasmic content, 
after the formation of membrane pores. Recently it has been demonstrated 
in mice models that pyroptosis requires gasdermin D to start. This protein is 
a substrate of inflammatory caspases by which it is cleaved generating N-
terminal fragment necessary to drive pyroptosis cell death. Although 
gasdermim D is essential for caspase 11-induced pyroptosis, mice Gsdmd-/- 
show pyroptosis cell death after a prolonged caspase 1 activation [184]. 
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However, the prolonged activation of caspase 1 can also drive the cells to 
necrosis death.  
On the other hand, Caspase 1 (also known as interleukin-converting 
enzyme - ICE) plays an important role in processing pro-IL-1β and IL-18, in 
the canonical inflammasome activation, two cytokines that are known 
because of their role in inflammation and their coordination of innate 
adaptive immune response [185]. To date, the exact mechanism by which 
IL-1β and IL-18 are secreted from the cells is unclear, in fact, their release 
is independent of the endoplasmic reticulum and Golgi. Different studies 
suggest that the release of these cytokines is due to cell lysis, at least in 
macrophages, but other cells type are able to secrete IL-1β and IL-18, and 
neutrophils, for example, release IL-1β without undergoing pyroptosis [186]. 
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4. CYTOKINES 
Cytokines are a group of small proteins secreted by cells with specific effect 
on the interactions and communications between cells. They can have 
autocrine, paracrine or endocrine action depending on where they act. 
Different cell types can secrete the same cytokine, which in turn can play 
different role, even if their activity are redundant, meaning that similar 
functions can be played by different cytokines. Moreover, they are named 
differently according to the role played in immune system or depending on 
the cells that produce them. Thus, they are divided in lymphokines, the 
ones made by the lymphocytes, monokines (made by monocytes), 
chemokines (that shows chemotactic activities) and finally interleukins (IL) 
that are produced by one leukocyte and act on other cells [187]. 
Among the Interleukins, IL-1 was the first to be discovered in 1977. The 
nomenclature of the members of this group of cytokines is continuously 
evolving and the new ILs are assigned to each family based on sequence 
homology, receptor chain similarities and also common biological 
properties. Thus, they are divided in five groups:  
- IL-1 family composed of 11 members that share minimal sequence 
homology and differences in their localization, maturation and 
secretion. However, they show similar biological properties. 
- IL-10 family composed of 9 members which show mainly anti-
inflammatory properties. 
- IL-12 family with its four members (IL-12, 23, 27 and 35) that share 
receptor and ligand chains but their functions are different 
depending on the cell type. 
- IL-17 family includes only one member, IL-17, with its sub-type (IL-
17A, B, C and D). 
- All the others interleukins share common y-chain, such as IL-2, 4, 7, 
9, 15 and 21, or chemokine activity, such as IL-8 and IL-16. 
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Finally, some interleukins can exert both inflammatory and anti- 
inflammatory actions [188].  
4.1 Interleukin 1 family 
The interleukin 1 family, with its 11 members (Table 3), is the most studied 
group of cytokines because it is closely linked to the innate immune 
system, more than the other known cytokines. Nevertheless, most of the IL-
1 members do not affect directly lymphocytes function but they act in an 
indirect manner. Virtually, the members of this family act on all the cells of 
the immune system promoting pro-inflammatory response. However, 
several study have also shown that some cytokines of this family can 
suppress inflammation, such as IL-18 binding protein or IL-1 receptor type 
1.  
The genes, which encode for IL-1 family members, are located on the long 
arm of chromosome 2, except IL-18 and IL-33 that are also closely related. 
The most characterized members of IL-1 family are IL-1α and IL-1β that are 
encoded by two distinct genes but they bind to the same receptor and 
share similar biological properties. The IL-1α precursor is constitutively 
expressed in epithelial cells and it mediates, after the release, early phases 
of sterile inflammation, while IL-1β is produced by hematopoietic cells. 
Unlike IL-1α precursor, which is fully active, IL-1β precursor needs to be 
cleaved to be released and become active [189]. Another important 
difference between them is their role in carcinogenesis. In fact, Krelin et 
colleagues have shown that mice deficient in IL-1β are more susceptible to 
develop cancer compare to the mice IL-1α knockout [190].  
In the last years, different studies have shed light on the role of another 
member of this family, which is IL-18, during inflammation to better 
understand how it acts. 
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Table 3: IL-1 family members. Image from [185]. 
 
4.2 Interleukin 18  
IL-18 was identified for the first time in 1989 as interferon-γ inducing factor, 
and for this it was firstly named IGIF, in mice suffering from endotoxin 
shock [191]. The human IL-18 gene is located on chromosome 11q22 and 
encode 193 amino acid protein [192]. hIL-18 shares 12% of amino acid 
sequence homologies with IL-1α and 19% with IL-1β. The regulation of IL-
18 gene differs from most of other cytokines. Human PBMC and epithelial 
cells express a steady-state IL-18 mRNA and constitutively accumulate IL-
18 precursor. The presence of the immature form of this cytokines ready to 
use allows the cell to rapidly produce the active protein in order to respond 
immediately to a stimulus [193]. As IL-1β, also IL-18 is synthetized as a 
biologically inactive precursor of 24 kDa, without a signal peptide. After 
stimulation, the precursor is cleaved into an active mature molecule of 18 
kDa by caspase-1. The important role of caspase-1 in this event has been 
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demonstrated in mice knockout for this converting enzyme, which showed a 
defect in IL-18 processing upon stimulation with lipopolysaccharide (LPS) 
[194], [195]. In addition, caspase-3 (CPP32) is also able to cleave both 
precursor and mature form of IL-18 generating biologically inactive 
degraded products. For this reason caspase-3 can be considered as a 
potential down-regulator of IL-18 [196] (Figure 13). Finally it has been 
identified a 29 kDa extracellular serine protease, called proteinase-3 (PR-
3), that can also cleave proIL-18.   
IL-18 is produced at high levels by activated macrophages and Kupffer 
cells. Literature data showed that also dendritic and Langerhans cells can 
produce this cytokine. 
The genomic analysis of the hIL-18 showed that the gene is composed by 
six exons and five introns (Figure 14).  Studies of the promoter activity in 
the 5’ flanking region of the hIL-18 gene demonstrated a constitutive 
expression of the gene in human myeloid cell lines, such as THP-1 or 
U937, and DNA protein binding experiments revealed also a specific 
binding of STAT-5. In fact, the transfection of STAT-5 in THP-1 or U937 
increases the promoter activity of IL-18  [197]. 
 
Moreover, in another study Kalina and colleagues showed that the 
consensus-binding site for PU.1 and a GC-rich region are the two important 
regulatory regions required for a basal IL-18 promoter activity in human 
myeloid cells [198].   
In addition, it has been demonstrated that the human keratinocytes are the 
major producer of IL-18 that can be found inside the cells in the inactive 
precursor in huge amounts [199], [200]. Moreover, a recent study showed 
an increase of IL-18 secretion by keratinocytes after UVB exposure [201].  
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Figure 13: Processing of hIL-18. Maturation of proIL-18 (24 kDA) into an 
active mature molecule of 18 kDa requires the cleavage by the intracellular 
cystein protease IL-1beta converting enzyme (ICE, caspase-1). The 
proteinase-3 (PR-3) may cleave extracellularly the proIL-18 into active 
form. CPP32 (caspase-3) cleaves both precursor and mature form into 
biologically inactive, degraded products. Image from [202]. 
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Figure 14 Genomic organization of human IL-18. The filled boxes 
indicate translated and the open boxes untranslated exon regions. Image 
from [203]. 
4.2.1 Biological properties 
When mature IL-18 is release from the cells it binds to a heterodimer 
receptor complex, formed by IL-18Rα and β chains. These two chains have 
a TIR domain in the intracellular portion and the binding of IL-18 to IL-18Rα 
recruits also the β chain to initiate the signal transduction. The adaptor 
protein MyD88 binds to TIR domain and phosphorylates IRAK, which in 
turn recruits TRAF-6, leading to the activation of the transcription factors of 
NF-κB and AP-1 (Figure 15) [204], [205].  
 
IL-18 modulates the immune system functions together with other 
cytokines. It acts with IL-12 to promote the production of interferon-γ (INF-
γ), Tumor necrosis factor alpha (TNF-α), CCL3, CCL4 and GM-CSF by 
CD4 Th1 and Natural Killer (NK) cells [206]. IL-18 can also play an 
important role in Th2 and Th17 responses inducing the naïve T cell to 
differentiate in Th2 cells  and promoting IL-17 production by CD4+ in 
absence of TCR engagement [207], [208]. In addition, IL-18 is involved in 
allergic diseases, including asthma, as well as in autoimmune disorders, 
such as lupus erythematosus, arthritis, Crohn’s disease [207]–[209]. 
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IL-18 activity is neutralized by a natural inhibitor named IL-18 binding 
protein (IL-18BP). It was discovered in human urine [212] and it has high 
affinity for the active mature form of IL-18.It acts blocking the interaction 
between the cytokine and its receptor, preventing the dimerization of the 
receptor [213]. IL-18BP belongs to Ig superfamily, it is constitutively 
produced by monocytes and macrophages, and it can be found in the blood 
of healthy people [214]. INF-γ induces IL-18BP secretion with negative-
feedback loop: it starts from IL-18-triggered INF-γ production that in turn 
induce IL-18BP gene expression to prevent excessive immune response. 
INF-γ, but also IL-27, induces STAT1 binding to IL-18BP promoter. These 
findings suggest a possible inti-inflammatory role of IL-18BP in skin 
diseases where there is an over production of IL-18 [215], [216].  
 
Interestingly, the study carried out by Schwarz and colleagues provided 
evidence for the involvement of IL-18 in DNA repair induced by UVB 
irradiation. The injection of IL-18 in mice exposed to UVB reduced the 
amounts of apoptotic keratinocytes and DNA damage into the cells. The 
same results were not observed in DNA-repair deficient mice confirming the 
ability of IL-18 to play a role in UVB-induced DNA repair   [217], [218].  
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Figure 15: IL-18 signal transduction. It involves MyD88 and IL-1 
receptor–associated kinases (IRAKs). TNF receptor–associated factor 
(TRAF)-6 is also a part of IL-18 signaling. TRAF-6 is required for the 
phosphorylation of mitogen-activated protein kinase (MAPK) p38. Image 
from [185]. 
 
4.2.2 Regulation of IL-18 expression during infection 
Many literature data shows the role of IL-18 during infection, both bacterial 
and viral. For example, IL-18 and IL-18R deficient mice are not able to 
respond to bacterial invasion [219]. Moreover, mice infected with vaccinia 
virus, herpes simplex type 1 (HSV-1) or encephalomyocarditis virus and 
treated with IL-18 exogenous survive to infection [217]–[219]. Several 
studies, both in vitro and in vivo, have demonstrate that many viruses 
stimulate the production of IL-18 mature protein, which in turn act 
promoting antiviral activities. Moreover, viruses evolved different strategies 
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to evade and block IL-18 pathway and the regulation of IL-18 production 
after infection often occurs at post-translational level. During pulmonary 
adenovirus infection, the virus inhibit IL-18 activity trough the production of 
a neutralizing anti-IL18 monoclonal antibody [223]. Poxviruses, such as 
Molluscum contagiosum, produce a protein similar to human IL-18BP, 
which acts blocking mammalian IL-18 activity [224]. 
In addition, E6 and E7 from HR HPV-16 inhibit the production of IL-18 in 
human peripheral blood mononuclear and NK cells. Moreover, studies 
conducted in primary human keratinocytes showed that E6 down regulates 
IL-18 expression, through the binding of the cytokines, while E7 
oncoprotein leads to an increased production of IL-18BP that neutralize IL-
18 activity [223]–[225]. 
Finally, there are some evidence that caspase-3 can be involved in the 
cleavage of IL-18 during virus infections. This enzyme is constitutively 
expressed in macrophage, such as caspase-1, and the infection can 
promote its activation that leads to IL-18 cleavage into two inactive 
fragments. Thus, caspase-3, acting in contrast to caspase-1, can promote 
viral immune evasion by the downregulation of IL-18 activity [196]. 
However, IL-18 can also promote viral infection. In vitro study have shown 
that IL-18 is able to enhance HIV-1 replication in monocyte and T cells 
[228], [229]. HIV-1 infection down regulates the endogenous levels of IL-18, 
thus PBMCs (peripheral blood mononuclear cells) from HIV-1+ patients are 
not able to respond to bacterial stimuli [230].   
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5. ROLE OF THE IMMUNE SYSTEM IN CANCER 
In 1909, Paul Ehrlich was the first to propose a protective role of the 
immune system against cancer [231]. Not long after, Coley reported that 
some patients showed a spontaneous tumor regression after developing 
post-surgical infections. These findings and other experimental results let 
him to hypothesize to apply immunotherapy for cancer regression [232]. 
Many years later, the theory of immunosurveillance of Burnet and Thomas 
was supported by the discovery that syngeneic mice were able to reject 
tumors upon secondary challenge and that those mice could be also 
vaccinated [233]. To support the hypothesis of the interaction between 
immune system and cancer, Schreiber and colleagues proposed the term 
“cancer immunoediting” [234], meaning that tumors are continuously edited 
by the immune system. This editing progress requires three stages during 
which immunogenic cancer cells are progressively eliminated (Figure 16). 
The first stage is the elimination phase: innate and adaptive immune 
response work together to detect and destroy cancer cells. The second 
stage is the equilibrium that is establish when the tumor is not completely 
eliminated. During this phase immune system cells and cancer cells 
interact in order to promote the development of alterations in both cell 
populations. The last stage is the escape; at this point cancer cells are less 
immunogenic and start to develop mechanism of evasion or to actively 
immunosuppress the host [235], [236]. To date, there are not definitive 
evidence for these stages in human tumors progression, but this is likely a 
useful conceptual framework to explain cancer immunosurveillance. For 
example, the immunoediting could be apply to the development of skin 
cancer because of its long latency and also because of the apparent 
spontaneous resolution of pre-neoplastic lesions. Nevertheless, the 
progression of these stages during skin cancer need to be confirmed in-
vivo.  
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Figure 16: A Paradigm of Cancer Immunosurveillance. Initially, there 
are pre-cancerous lesions, such as the illustrated actinic keratosis (upper 
left), in which elimination may occur due to the killing of altered cells by 
elements of the immune system. Alternatively, a stage of equilibrium may 
result where tumor cells and immune cells interact during a period of stable 
tumor size. During this period, immune cells may select to more aggressive 
and/or less immunogenic tumor variants. Eventually, perhaps as a result of 
this process, the tumor expands and continues to grow despite the 
presence of an immune response. This continued growth can be observed 
in invasive squamous cell carcinoma which typically does not 
spontaneously regress (lower right). Image from [237].  
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As said at the beginning, UVB radiation represents one of the most 
important risk factor for skin cancer development. In fact, chronic UVB 
exposure leads to the formation of actin keratosis and as final stage 
development of SCC. On the other hand, intermittent high dose of UVB 
causes mostly BCC and then melanoma [238]. Moreover, many studies 
underline the dramatic effect of UV exposure on immune system. Kripke 
and colleagues showed the antigenicity and immunogenicity of UV-induced 
skin cancers because these tumors are rejected by syngeneic mice but not 
by mice exposed to UVB. A possible explanation could be that the 
exposure induces “suppressor T cells” that in turn might inhibit the ability of 
the mice to reject UV-induced tumor, compared to the non-exposed mice 
[239].  
UVB immunosuppression can be local, with the depletion and/or 
downregulation of the capability of the Langerhans cells to present the 
antigens, and systemic, through the stimulation of keratinocytes and 
macrophages to produce cytokines with high impact on systemic 
immunosuppression.  
DNA damage and the production of ROS and cytokines, which lead to 
chronic inflammation, cooperate to mutagenize epithelial cells in order to 
create an immunosuppressive environment that supports cancer formation 
and progression [239]–[241].  
5.1  Inflammasome activation in cancer 
Different studies support the hypothesis of a link between inflammation and 
cancer development. In fact, chronic inflammatory response are often 
associated with many types of cancer playing an important role during 
cancer development.  
Literature data showed that different subsets of immune cells are involved 
in cancer progression and more often inflammasome complexes are 
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activated in response to danger signals that come from tumors but this 
activation can play a different role in cancer progression depending on the 
specific context. For instance, the etiological link between tumor 
development and chronic inflammation is well known and documented for 
cancers of the gastrointestinal tract. In this case, the chronic inflammation 
of the stomach, due to Helicobacter pylori infection or other causes, 
provokes a continuous activation of inflammasome complexes that in turn 
causes an up-regulation of pro-inflammatory cytokine secretion. To support 
this finding, Tu and colleagues showed that stomach-specific release of 
pro-inflammatory cytokines induces inflammation and high risk to develop 
cancer in mice [243]. Moreover, Jee and colleagues demonstrated that 
there is a decrease of caspase-1 expression in 19% of gastric cancer cases 
[244]. In addition, Allen et al. support this etiological study arguing that mice 
knockout for different inflammasome components, such as caspase-1, ASC 
or NLRP3, show increased and recurring acute colitis and tumorigenesis 
compared to wild type mice [245]. On the other hand, it has also been 
reported that inflammasome complexes, such as NLRP6, can suppress 
tumor progression in mouse models [246].  
There are no direct evidence about the involvement of inflammasome in 
breast cancer, but different studies demonstrated that inflammasome 
activation could play an important role in hepatitis C-associated 
hepatocellular carcinoma. In fact, it is known that HCV infection activates 
NLRP3 inflammasome [247]. 
Furthermore, the involvement of inflammation in melanoma is also known. 
Okamoto reported that there is a constitutive activation of NLRP3 
inflammasome in skin cancer [248] but the function of active 
inflammasomes can be different depending on the cell type, where the 
complex in activated, as well as the stage of the cancers. For example, in 
non-metastatic cells, ASC expression decrease the activity of NF-κB 
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leading to a reduction of the tumor while the opposite behavior is shown in 
metastatic melanoma cells [249].  
 
Recently, the analysis of the expression of inflammasome components in 
cSCC showed that there is a strong up-regulation of AIM2 expression, both 
at mRNA and protein levels, compared to normal human keratinocytes. In 
addition, the knockout of the inflammasome AIM2 in those cells leads to a 
reduction of the viability as well as of the invasiveness of the cSCC [250].  
Inflammasome-mediated secretion of pro-inflammatory cytokines, such as 
IL-18, plays a critical role in innate immune response as well as in adaptive 
immune response. Thus, it is not surprising to think that inflammasome can 
modulate immune system response towards tumors development and 
therapy.  
5.2  IL18 a double-edged sword in cancer 
Interleukin 18 shows a dual role in cancer progression: it can promote 
tumor development and progression, or oppositely limit tumor growth.  
High level of expression and secretion of IL-18 have been found in patients 
with cancers, such SCC, melanoma or others skin cancer cell lines [251]. 
IL-18 seems to promote tumor progression stimulating angiogenesis and 
metastasis. It is well known that angiogenesis is an important event not 
only during inflammatory response and would healing, but also during 
tumor progression, because solid tumors require oxygen and nutrient to 
grow [252]. High level of IL-18 are detected in invasive tumor tissue of 
gastric cancer where the over-expression of the pro-inflammatory cytokine 
is associated with the formation of new blood vessel. Kim at colleagues 
demonstrated that the pretreatment of gastric cancer cells with JNK 
inhibitor lead to a reduction of trombospondin-1 (a pro-angiogenic factor in 
gastric cancer) expression  IL-18- mediated [253].  
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In addition, several studies, conducted in patient suffering of rheumatoid 
arthritis, demonstrated that IL-18 stimulates production of vascular 
endothelial grow factor (VEGF) both at mRNA and protein level, supporting 
the theory that IL-18 is a direct angiogenic stimulator [254]. Moreover, 
angiogenic factors can also induce IL-18 maturation suggesting a positive-
feedback mechanism of regulation between the cytokine and VEGF 
production in cancer. 
The ability to metastasize is important for cancer progression and 
malignancy and IL-18 can acts as a cell migration stimulator in gastric 
cancer as well as in melanoma. IL-18 increases the expression of the 
metalloproteinase 9 (MMP-9) both at mRNA and protein level in leukemia 
cell line, promoting the degradation of the ECM (extracellular matrix) 
surrounding the cells and the invasion ability [255], [256].  
In addition, as previously mentioned, the immune system is able to detect 
and eliminate cancerous cells, however cancer cells have developed 
several mechanism to evade the immune response. For example, in 
melanoma cells IL-18 promotes the expression of Fas ligand giving them 
resistance to immune surveillance, because the cells of the immune system 
are not able to recognize cancer cells. Moreover, cancer cells induce 
apoptotic death of immune cells because of the expression of Fas ligand 
[257]. 
Finally, there are also several evidence of the anti-cancer effects of IL-18. 
During Helicobacter pylori infection of gastric mucosa, high level of IL-18 
expression may contribute to Th1 activation and response [258]. 
Furthermore, Myd88 KO-mice with a defect in IL-18 production show more 
susceptibility to develop colorectal cancer [259] as well as mice Il-18-/-. 
Nishio and colleagues reported also that the administration of recombinant 
IL-18 in syngeneic mice mediates the regression of melanoma or sarcoma 
through the activation of CD4+ and NK cells [260].  
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IL-18 may have anti-tumor effects in some human cancer. Nonetheless, 
ovarian and colon epithelia produce and release mature IL-18 in response 
to pathogens but during neoplastic transformation they are unable to 
process IL-18 because of a defect in caspase-1 expression [261], [262]. In 
addition, in prostatic and ovarian cancer, high levels of IL-18BP have been 
detected. This event may inhibit the therapeutic and anti-cancer effect of IL-
18, representing a probable mechanism of immune escape [263].  
More often, IL-18 does not act alone but in combination with other 
cytokines, such as IL-12, or costimulatory molecules in order to increase its 
anti-tumor effects.  
 
In conclusion, the current literature underlines the important role of immune 
system in development, progression and elimination of cancers cells, 
emphasizing the double and divergent behavior of this system in different 
neoplastic conditions. Inflammasomes with its several components could 
be considered a promising target for prevention as well as for cancer 
therapy. However, additional studies are required to better shed light on the 
mechanisms involved in immune surveillance failure with the consequent 
development and progression of cancer.  
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AIM OF THE STUDY 
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UV-radiation represents a key risk factor for the development of non-
melanoma skin cancer (NMSC) [5], [240]. Moreover, several studies have 
shown a greater tendency to develop skin cancer in immunocompromised 
individuals, emphasizing a potential role of infectious agents in these 
events [9]. Among them, the human beta papillomavirus types, that 
normally colonize the skin, are suspected to be involved in the development 
of NMSC, acting as a co-risk factor together with ultraviolet radiation.  This 
hypothesis is mainly supported by the fact that people suffering of 
epidermodysplasia verruciformis, a skin disease due to an autosomal 
recessive disorder, are more susceptible to β-HPV infections and also to 
the development of skin squamous cell carcinoma (SCC) after sun-
exposure [27]. Functional studies, both in in vivo and in vitro experimental 
models, have highlighted the oncogenic properties of E6 and E7 proteins of 
some HPV β-type and their ability to evade the immune response of the 
host, in order to efficiently produce new progeny. For instance, Caldeira 
and colleagues have characterized the transforming properties of E6 and 
E7 of β-HPV38, showing their ability to immortalize human primary 
keratinocytes and to inactivate the functions of the retinoblastoma protein, 
pRb, and the tumor suppressor factor, p53 [105]. In addition, previous 
studies conducted in our group on transgenic mouse model, which 
expresses of E6 and E7 of HPV38 in the skin under the control of K14 
promoter, showed that the transgenic mice do not present any spontaneous 
formation of cancer lesion under physiological condition, while after UV-
exposure they develop actinic keratosis-like lesions that are considered as 
a precursor of SCC in human. However, the wild type mice do not develop 
any kind of lesion after the irradiation [113]. 
Furthermore, independent studies carried out on keratinocyte cell lines 
provided evidence that the exposure to ultraviolet radiation causes the 
activation of pathways involved in the innate immune response, such as the 
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inflammasome pathway, which leads to the secretion of specific pro-
inflammatory cytokines, like IL-1β or IL-18 [201]. More important, it has 
been reported that in the presence of E6 and E7 from α-HPV16 as well as 
β-HPV38 the secretion of the pro-inflammatory cytokine IL-1β is impaired 
after UVB exposure [264]. 
Lastly, it is also known the possible involvement of IL-18 in DNA repair after 
UV irradiation [217], [218], as well as its potential role in cancer 
development [259] .    
Therefore, based on this literature data the aim of this work is to evaluate 
and analyze the mechanisms involved in the deregulation of UV-activated 
inflammasome by E6 and E7 from HPV38 in human keratinocytes in order 
to further corroborate the hypothesis of the cooperation between sun 
exposure and β-HPV infection in the development of non-melanoma skin 
cancer. 
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MATERIALS AND METHODS 
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1. CELL CULTURE AND TREATMENTS 
Experiments were carried out in human primary foreskin keratinocytes 
(HPKs), HPKs expressing E6 and E7 from HPV38, HPKs hTERT and   
HPKs hTERT expressing E6 and E7 from HPV38. 
Primary cultures of human epithelial keratinocytes and hTERT cell line 
were cultured together with NIH 3T3 feeder layers in FAD medium 
containing: 3 parts Ham's F12, 1 part DMEM, 2,5% fetal calf serum, insulin 
(5 μg/ml), epidermal growth factor (10 ng/ml), cholera toxin (8.4 ng/ml), 
adenine (24 μg/ml), hydrocortisone (0.4 μg/ml) and 1% of pen/strep 
preparation. Feeder layers were prepared by treating NIH 3T3 with 
mitomycin for 2h. NIH 3T3 cells were cultured in Dulbecco's modified 
Eagle's medium (DMEM) supplement with 10% fetal calf serum and 1% 
pen/strep preparation. HPKs expressing E6 and E7 from HPV38 and HPKs 
hTERT, with or without E6 and E7 from HPV38, were generated and 
cultured as previously described [105]. 
Transient transfection experiments were performed using TransIT®-
Keratinocyte Transfection Reagent (Mirus) according to the manufacturer 
protocols. 
Cells were exposed to 50 mj/cm2 UVB dose with a thin layer of phosphate-
buffered saline (PBS) using the BIO SUN UV Light Irradiation apparatus 
(Vilber Lourmat). Cells were then incubated at 37°C in a humidified 
chamber and harvested at specific time points.  
2. TRANSCRIPTOME ANALYSIS 
Wild-type (WT) and HPV38 E6/E7 Tg mice were UV-irradiated 5 times or 
not irradiated. After 24h, skin was collected and expression of cellular 
genes was determined by Illumina array system (Illumina, San Diego,CA). 
The heat map was generated by comparing the expression levels of cellular 
genes of UV-exposed wild-type and HPV38 E6/E7 Tg animals. Only the 
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transcripts that showed a standard deviation lower than 0.9 were used for 
the analysis, and only differences that were significant with P<0.05 in a two-
group test were considered. 
3. RNA EXTRACTION AND RT-qPCR 
Total RNA was isolated from keratinocytes using NucleoSpin RNA protocol 
(MACHEREY-NAGEL) and the cDNA generated with RevertAid H minus 
First Strand cDNA Synthesis Kit (Thermo Scientific).  
The resulting cDNA was amplified using specific primers. The sequences of 
the primers are listed in the table 4 below. GAPDH was used as the internal 
control for each reaction. 
4. SDS-PAGE AND IMMUNOBLOTTING 
Cells were lysed using Ripa buffer (50mM TrisHCl, 150mM NaCl, 10mM 
MgCl2, 0,5% Sodium Deoxycholate, 0.1% SDS, 1% Np-40 ) supplemented 
with cOmplete Protease Inhibitor mixture (Roche).  
Proteins from the supernatant of the cell cultures were extracted according 
the following protocol:  
Keep 500 µL supernatant from the cells culture (after the treatment, cells 
were cultured in OptiMEM without serum medium to facilitate the protein 
extraction). To precipitate supernatant:  
• add 100 µL chloroform + 500 µL methanol 
• Vortex         
• Centrifuge 3 min 13000 rpm 4oC 
• Trash the aqueous phase without touching the white disc 
(precipitated proteins) 
• Add 500 µL methanol and vortex 
• Centrifuge 3 min 13000 rpm 4oC. 
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• Carefully remove the solution with a tip 
• Dry the pellet 5 min at RT 
• Add 35 µL Laemmli Buffer 4X (BioRad) + DTT (50 mM) or + β-
mercaptoethanol (Sigma) 
• Heat 10 min at 90oC and load a third of the total volume of the 
samples. 
Samples were resolved by SDS-PAGE and transferred to membranes 
PVDF membrane (PERKIN ELMER). Membranes were blocked in 5% 
nonfat milk and incubated overnight at 4°C with the appropriate primary Ab.   
Samples were resolved by SDS-PAGE and transferred to membranes 
PVDF membrane (PERKIN ELMER). Membranes were blocked in 5% 
nonfat milk and incubated overnight at 4°C with the appropriate primary Ab.  
Membranes were probed with the following primary antibodies: Anti-pro-IL-
18 (Human) mAb (MBL- M156-3), Anti-IL-18 (Human) pAb (MBL-PM014), 
AIM2 (D5X7K, Cell Signalling), anti-NLRP1/NALP1 (human) pAb (AL176, 
AdipoGen®, Life Sciences), p53 DO-1 (sc-126, Santa Cruz biotechnology, 
INC), β-actin (MP, Biomedicals) and GAPDH (6C5, sc-32233 Santa Cruz 
biotechnology, INC) were used as lading control. Membranes were then 
incubated with the appropriate HRP-conjugated secondary antibody (anti- 
rabbit and anti-mouse from Sigma). Proteins were detected using Clarity™ 
Western ECL Substrate (Biorad) and ChemiDoc XRS imaging system (Bio-
Rad). 
5. ELISA ASSAY 
The concentration of IL-18 in the culture supernatant was measured by a 
commercially available ELISA (K151MCD-1, Meso Scale Discovery). After 
stimulation, cell culture supernatants were collected, centrifuged at 1500 
rpm for 10 min at 4 ºC and concentrated using Amicon Ultra-4 Centrifugal 
Filter 3 (Millipore) and then added to coated wells. Elisa assay was 
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performed following the protocol: 
https://www.mesoscale.com/~/media/files/product%20inserts/human%20il-
18.pdf. Relative absorbance was measured at 450 nm, and the IL-18 
concentration was calculated using a standard curve. Each supernatant 
was analyzed in duplicate. 
6. LUCIFERASE ASSAY 
Transient transfection experiments were performed using TransIT®-
Keratinocyte Transfection Reagent (Mirus) according to the manufacturer 
protocols. hTERT cells were transfected with pGL3 firefly luciferase IL-18 
short or long promoter vectors (1 μg). A pRL-Renilla reporter vector (10 ng) 
was used as an internal control. After 24 hours the cells were harvested, 
lysed and luciferase activity was measured using a dual-luciferase reporter 
assay system (Promega). The expression of firefly luciferase relative to 
Renilla luciferase was expressed in relative luminescence units (RLU). 
7. CHROMATIN IMMUNOPRECIPITATION 
Chromatin immunoprecipitation (ChIP) was performed with Shearing ChIP 
and OneDay ChIP kits (Diagenode) according to the manufacturer’s 
instruction. Briefly, cells were sonicated to obtain DNA fragments of 200–
500 bp. Sheared chromatin was immunoprecipitated with isotype control 
IgG or with the indicated antibodies. The eluted DNA was used as a 
template for qPCR. Primers for qPCR are listed in Table 5 below. 
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8. STATISTICAL ANALYSIS 
Statistical significance was determined by Student t-tests. Statistically 
significant p values of each experiment are indicated in the corresponding 
Figure legends, P < 0.05 (*); P < 0.01 (**); ns = non-significant. Error bars 
in the graphs represent the standard deviation.  
 
 
 
Table 4: Sequences of primers used for RT-qPCR analyses.  
 
 
 
Table 5: Sequences of primers used for ChIP analyses  
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1. EFFECT OF UVB IRRADIATION ON GENE EXPRESSION PROFILE 
OF HPV38 E6/E7 TRANSGENIC MICE  
In our group a transgenic (Tg) mouse model has been generated that 
constitutively expresses E6 and E7 from HPV38 in the skin epithelium 
under the control of K14 promoter. This model has been used to explore 
the interaction between β-HPV38 E6 and E7 and the environmental risk 
factors, such as UVB exposure, that are involved in the development of 
NMSC.  Previous results obtained by our group have shown that chronic 
exposure to UVB of HPV38 E6/E7 Tg mice primarily resulted in the 
development of actinic keratosis-like lesions that are considered precursors 
of SCC in humans and few weeks later the mice developed SCC. 
Conversely, the wild type mice did not develop any kind of lesions when 
exposed to the same UVB dose [113]. Similarly to the development of UV-
induced skin lesions, HPV38 E6/E7 Tg mice accumulated thousands UVB-
induced C>T mutations during the long-term UV irradiation, while only a 
small number of mutations were detected in the skin of the wild-type 
animals exposed to the same treatment (unpublished data).  
To better understand the molecular mechanisms of the cooperation 
between HPV38 E6 and E7 and exposure to UVB, we analyzed the entire 
transcriptome profile in the skin of WT and HPV38 E6/E7 Tg mice that were 
either exposed or not-exposed to UV irradiation. The mice (3x Tg / 3x WT) 
were irradiated for 5 days with a daily dose of 450mJ/cm2 or not irradiated 
and then the skin was collected to determine the cellular genes expression 
profile by Illumina array. The analysis pointed out that more than 300 genes 
were deregulated in the skin of the HPV38 E6/E7 Tg mice after UVB 
exposure, compared to WT animals. In particular, HPV38 E6 and E7 
oncoproteins were able to downregulate the expression of genes involved 
in the inflammasome complexes or the downstream effector, such as the 
pro-inflammatory cytokine IL-18. The results are shown in the heat map in 
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Figure 17a. To confirm the transcriptome findings, RT-qPCR was 
performed. The skin of the mice, both WT and Tg, was irradiated with one 
dose of 50mj/cm2 for 5 consecutive days and after 24h the IL-18 mRNA 
level was determined. Results are reported in figure 17b. 
As we can observe in Figure 17b, RT-qPCR confirmed the transcriptome 
results showing that IL-18 expression was upregulated in wild-type mice 
after the exposure to UVB, while it was strongly inhibited in the skin of 
HPV38 E6/E7 Tg mice.  
Interestingly, the study carried out by Schwarz and colleagues showed that 
the injection of recombinant IL-18 in mice exposed to UVB reduced the 
amounts of apoptotic keratinocytes and DNA damage into the cells, 
providing evidence for a link between IL-18 and the accumulation of 
damaged cells by UVB irradiation [217], [218]. Based on this literature data, 
we performed an experiment injecting recombinant IL-18 (rIL-18) 
subcutaneously in HPV38 E6/E7 Tg mice. The injection was performed 
twice per week during the well-established chronic UV-irradiation protocol 
for 30 weeks [113]. As shown in Figure 17c, the injection of rIL-18 into the 
mice caused a delay in UVB-induced skin lesions. 
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Figure 17. E6 and E7 of HPV38 alter the cellular gene expression 
induced by UVB. (A)The heat map was generated comparing the 
expression levels of cellular genes after the exposure to UVB of the wild 
type and Tg mice. (B) IL-18 mRNA level was determined by RT-qPCR. The 
amount of IL-18 mRNA extracted from non-treated Tg keratinocytes is 
taken as reference (=1). (C) rIL-18 injection causes a delay in UVB-
induced skin lesions. Tg mice were UVB-irradiated for 30 weeks. One 
group received 300 ng injections of rIL-18 twice per week. The graph 
reports the number of skin lesions in each mouse, treated or non-treated 
with IL-18.  
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2. MODULATION OF IL-18 EXPRESSION AFTER UVB EXPOSURE IN 
HUMAN KERATINOCYTES EXPRESSING OR NOT HPV38 E6 AND E7 
To gain further insight into the mechanism of UV-induced IL-18 expression 
and the role played by HPV38 E6 and E7 in these events, we used human 
primary keratinocytes (HPKs), expressing or not the two viral oncoproteins, 
as experimental model. Cells were irradiated with one dose of UVB 
(50mj/cm2) and collected after 4h. As observed in the animal model and 
accordingly to the literature data [201], RT-qPCR showed an up-regulation 
of IL-18 mRNA level (Figure 18a upper graph) in HPKs after 4h post 
irradiation. Conversely, the presence of E6 and E7 of HPV38 strongly 
downregulated this activation.  
Interestingly, HPV38 E6 and E7 were also able to block the cleavage and 
the consequent release of IL-18 protein as shown in the western blot 
analysis (Figure 18a left) and the ELISA assay (Figure 18a right), indicating 
that HPV38 uses transcriptional and post-translational mechanisms to 
inhibit IL-18 production and secretion.   
Due to limited life span of primary cells, several experiments were 
hampered using this in vitro experimental model. To overcome this 
problem, we have used alternative models such as human spontaneously 
immortalized keratinocytes, i.e. HaCat and NIKs cell lines, or we developed 
HPKs expressing the human telomerase reverse transcriptase (hTERT) 
gene, in order to prolong the life span of the primary cells. All the cell lines 
were stably transduced with a retrovirus expressing the two HPV38 
oncogenes, E6 and E7. Cells were irradiated with one dose of UVB 
(50mj/cm2) and collected after 4h.  
Western Blot analysis showed that after UVB exposure all the cell lines are 
able to cleave IL-18 and release the protein into the supernatant (Figure 
18b). As observed in HPKs, the expression of HPV38 E6 and E7 genes 
strongly inhibited IL-18 secretion, indicating that the HPV38 mechanism in 
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altering the production of the mature form of IL-18 via post-translational 
mechanisms is conserved in several in vitro experimental models. 
Surprisingly, none of these three cell lines were able to modulate IL-18 
mRNA expression when exposed to UVB radiation, as we can see in the 
RT-qPCR (Figure 18c). However, the expression of the two viral 
oncoproteins strongly downregulated the basal expression of IL-18 both at 
mRNA and protein levels (Figure 18).  
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Figure 18: Human primary keratinocytes expressing HPV38 E6 and E7 
inhibit IL-18 mRNA expression and secretion after UVB exposure. 
(A)Total RNA and total protein were extracted and the supernatant was 
collected from HPKs irradiated with UVB or not. IL-18 expression levels 
were measured by RT-q PCR and using GAPDH gene as an internal 
control (upper panel). Proteins extracts were analyzed by immunoblot for 
the indicated antibody (left panel). The supernatant was collected and 
concentrated, and IL-18 concentration was measured by ELISA assay 
(right panel). Data shown are the mean of three independent experiments 
carried out on three different HPKs from healthy donors. *, P<0.05; **, 
P<0.01; ns, non-significant. Human immortalized keratinocytes 
modulate IL-18 expression after UVB exposure only at protein level. 
(B, C) Total protein and total RNA were extracted from HaCat, NIKs and 
HPKs hTERT cell lines irradiated with UVB (50mj/cm2) or not. Proteins 
extracts, from cell lysate and from the supernatant, were analyzed by 
immunoblot for the indicated antibody and bands intensity were quantified 
and normalized to β-actin (panel B). IL-18 expression levels were 
measured by RT-q PCR and using GAPDH gene as internal control (panel 
C). Data shown are the mean of three independent experiments. *, P<0.05; 
**, P<0.01; ns, non-significant. 
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3. ANALYSIS OF THE TRANSCRIPTIONAL REGULATION OF IL-18 
GENE. 
Based on our results that highlighted the loss of IL-18 transcriptional 
activation by UV irradiation in immortalized keratinocytes (i.e. HaCaT, NIKs 
and hTERT HPKs), in comparison to HPKs, we hypothesized that 
immortalization of these cells correlated with alteration of the transcriptional 
functions of potential  transcription factors involved in the UV-induced IL-18 
expression. Moreover, the analysis of IL-18 mRNA expression of the 
immortalized keratinocytes showed a strong upregulation of the basal level 
of IL-18 compared with HPKs, an event strongly appreciate in hTERT 
HPKs.  
It is well-known that UVB radiation causes an accumulation of p53 in HPKs 
[265], [266], thus it is possible that the induction of IL-18 in UV-exposed 
keratinocytes is mediated by p53. Interestingly, it has been reported that 
ectopic expression of hTERT in HPKs induces p53 accumulation [267], 
[268]. Based on this literature data, we evaluated whether in the 
immortalized keratinocytes the IL-18 basal mRNA levels correlate with p53 
expression levels. As shown in Figure 19a, p53 levels tightly correlated with 
the basal levels of IL-18 expression. In particular, p53 and IL-18 were 
strongly accumulated in hTERT HPKS (Figure 19a).  
To further corroborate the link of p53 with IL-18 expression, we generated 
p53 knockout hTERT HPKs using Crispr/Cas9 technology. Expression of 
p53 was efficiently silenced when the gene was deleted compared to the 
control cells transfected with Crispr/Cas9 vector containing the scramble 
sequence. IL-18 mRNA expression was evaluated by RT-qPCR that 
showed a downregulation of the cytokine expression after p53 knockdown 
(Figure 19b). These results support our hypothesis of the possible role 
played by p53 in this event. 
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To evaluate the ability of HPV38 E6 and E7 in the repression of IL-18 
promoter activity, we performed a transient transfection experiment in 
hTERT HPKs cell line using a vector containing the isolated IL-18 promoter 
cloned in front of the luciferase reporter gene. In agreement with the RT-
PCR data, IL-18 promoter is very active in hTERT HPKs (Figure 19c). A 
small deletion of approximately 500 nucleotides (short promoter) resulted in 
the loss of IL-18 promoter activity, indicating that this region contains key 
response elements. In hTERT HPKs, that were stably transduced or 
transiently transfected with E6 and E7, we observed a strong repression of 
IL-18 promoter. In addition, the results obtained with the transient 
transfection of HPV38 E6 or E7 alone showed that both are able to 
efficiently repress the activity of IL-18 promoter.  
In order to clarify the role played by p53 in the modulation IL-18 mRNA 
expression, we investigated the IL-18 promoter by using TFBIND 
bioinformatics tools. The analysis revealed the presence of 15 putative 
binding sites for p53. Next, we divided the promoter in five regions and 
designed five different pairs of primers in order to cover all the putative 
binding sites (Figure 19d). We performed chromatin immunoprecipitation 
(ChIP) assays in hTERT HPKs and HPV38 E6/E7 hTERT HPKs cells. The 
results showed that p53 is mainly recruited in two distinct regions of the 
promoters, which includes four p53 putative responsive elements. 
Importantly, HPV38 E6 and E7 efficiently prevent p53 recruitment to these 
IL-18 promoter regions (Figure 19d). 
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Figure 19: Possible role of p53 in the transcriptional regulation of IL-
18 gene. (A)Total RNA and total protein were extracted from HPKs, HaCat, 
NIKs and hTERT HPKs cell lines expressing or not HPV38 E6 and E7. IL-
18 expression levels were measured by RT-qPCR and using GAPDH gene 
as an internal control. Proteins extracts from cell lysate were analyzed by 
immunoblot for the indicated antibodies and bands intensity were quantified 
and normalized to β-actin. (B)Total RNA and total protein were extracted 
from hTERT HPKs expressing wt p53 (scramble) or Crispr/Cas9 deleted 
p53 (crisp p53). IL-18 expression levels were analyzed by RT-q PCR while 
the efficiency of p53 knockdown was determined by western blot analysis. 
Data shown are the mean of two independent experiments. *, P<0.05; **, 
P<0.01. (C) The promoter activity of IL-18 gene is repressed in hTERT 
HPKs cell line expressing E6 and E7 of HPV38. Scheme of IL-18 
promoter luciferase constructs: the long promoter (-1335/+161) and the 
short promoter (-751/+42). hTERT HPKs and hTERT HPKs HPV38 E6/E7 
cells were transfected with the two promoter constructs. After 24h cells 
were harvested and the promoter activity was measured (left panel). 
hTERT HPKs were co-transfected with IL-18 short and long promoters and 
with E6 and E7 together or alone. After 24 hours, the cells were harvested 
and the promoter activity was measured (right panel). Data are the average 
of three independent experiments performed in triplicate. *, P<0.05; **, 
P<0.01. (D) p53 is recruited on IL-18 promoter. IL-18 promoter region: 
exon 1 from 3666 to 5000 (left panel). ChIP was performed in hTERT HPKs 
and hTERT HPKs HPV38 E6/E7 cells using p53 antibody. Part of the total 
chromatin fraction (1/10) was used as input. RT-qPCR was performed 
using specific primers flanking the five regions of IL-18 promoter. The 
histogram shows the percentage of p53 binding to the promoter after the 
subtraction of the background of nonspecific IgG control (right panel). Data 
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are expressed as percentage of input and represent the average of three 
independent experiments. *, P<0.05; **, P<0.01. 
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4. RESPONSES OF OTHER COMPONENTS OF THE INFLAMMASOME 
COMPLEXES AFTER UVB EXPOSURE IN HPKs. 
Taking into account that IL-18 is the final downstream effector of the 
inflammasome activation, we further evaluated the relationship between 
HPV38 E6/E7 and UVB exposure in innate immune response activation. 
HPKs or HPV38 E6/E7 HPKs were irradiated with UVB (50mj/cm2) and 
collected 4 hours after irradiation. RT-qPCR and Western Blot analysis 
showed the capability of HPKs to increase the levels of AIM2 and the 
relative adaptor protein ASC after the exposure to UVB (Figure 20a), while 
NLRP1 inflammasome, which is typically associated to keratinocytes [128] 
appeared to be not involved in this event (Figure 20b). Interestingly, the 
expression of HPV38 E6 and E7 oncoproteins in hTERT HPKs abolished 
the UV-induced up-regulation of AIM2 and ASC.  
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Figure 20: UVB exposure induces an upregulation of AIM2 and ASC 
inflammasome complex in HPKs. (A, B) Total RNA and total proteins 
were extracted from HPKs and HPKs HPV38E6/E7 irradiated with UVB 
(50mj/cm2) or not and collected after 4 hours. AIM2, ASC and NLRP1 
expression levels were measured by RT-q PCR and using GAPDH gene as 
an internal control (upper panels). Protein extracts from cell lysates were 
analyzed by immunoblot for the indicated antibodies and bands intensity 
were quantified and normalized to β-actin (bottom panels). Data shown are 
the mean of three independent experiments. *, P<0.05; **, P<0.01. 
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Several epidemiological studies have reported that the incidence of non-
melanoma skin cancers (NMSCs) in fair skinned adult populations has 
considerably increased in the last years, exceeding that of all other cancers 
[1], [2], [5]. This phenomenon has generated a great interest in 
understanding the pathogenesis of this type of cancer in order to find new 
non-invasive treatments. Many risk factors have been associated to the 
development of NMSCs but undoubtedly the most important is the sun 
exposure. Indeed, the ultraviolet (UV) radiation causes skin damage that 
after repeated exposure can lead to the formation of skin lesions and then 
develop into skin cancer [8], [10]. Moreover, several clues have indicated 
infectious agents as additional risk factor for skin carcinogenesis and this 
hypothesis is supported by the evidence that people with a compromised 
immune system, such as organ transplant recipients (OTRs), are much 
more susceptible to develop NMSC compared to the normal population [9]. 
In addition, our skin is colonized by different infectious agents and, among 
them, the cutaneous human papillomaviruses, belonging to the beta genus, 
are considered the most likely additional etiological factor for NMSC. In 
fact, β-HPV types were isolated for the first time in EV patients, who are 
highly susceptible to β-HPV infection and UV-induced skin carcinogenesis 
[27], [29], [105]. All these findings support the potential role of β-HPV types 
in the development of skin cancer, together with sun-exposure. Moreover, 
several functional studies carried out in in vitro as well as in in vivo 
experimental models, have also highlighted the transforming properties of 
the viral proteins E6 and E7 from some β-HPV types. For instance, the two 
viral proteins are able to deregulate key molecular pathways related to cell 
survival, proliferation, apoptosis and DNA repair [108]. To date, only E6 and 
E7 from β-HPV 38 and 49 have demonstrated the ability to immortalize 
human primary keratinocytes, like the two oncoproteins of HPV16. HPV38 
E7 associates with pRb, promoting its degradation, while E6 is not able to 
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promote p53 degradation, as it has been shown for HPV16. Moreover, 
HPV38 is able to alter the deregulation of the p53 network by inducing the 
accumulation of a p53 antagonist, ΔNp73α, which in turn inhibits the 
expression of several p53-regulated-genes encoding positive regulators of 
apoptosis [109], [110].  
Based on these in vitro results, our group generated a mouse model to 
further investigate the oncogenic properties of HPV38 and the interaction 
between E6/E7 and the environmental risk factors potentially involved in 
skin carcinogenesis, such as UV radiation. In this mouse model, HPV38 E6 
and E7 are expressed in the undifferentiated basal level of the epithelia 
under the control of the keratin 14 (K14) promoter. 
The experiments carried out using this mouse model showed that Tg mice 
were highly susceptible to UV irradiation since their exposure to UVB 
caused the development of skin pre-malignant lesions and subsequently 
squamous cell carcinoma. In contrast, wild type mice exposed to the same 
doses of UV irradiation did not develop any lesions [113]. These findings 
indicated that HPV38 has developed mechanisms to alter the response of 
normal skin keratinocytes to UV irradiation, creating a favorable 
environment for the development of skin cancer.  
However, the mechanism of this synergism has not yet been elucidated 
and our ongoing studies are now focused on better understanding the 
events involved in UV-induced NMSC, both in in vivo and in in vitro models 
expressing E6 and E7 from HPV38.  
Our findings obtained in HPV38 E6/E7 Tg mice showed that the 
development of skin cancer tightly correlated with the accumulation of the 
typical C>T mutations induced by UV irradiation. In addition, the analysis of 
the entire transcriptome profile in wild-type and Tg mice non-exposed or 
exposed to UV irradiation revealed that more than 300 genes were 
deregulated in the Tg mice after the UV exposure, compared to the wild-
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type animals. In particular, the viral oncoproteins were able to downregulate 
the expression of proteins involved in the inflammasome complexes or the 
downstream effectors, such as pro inflammatory cytokines belonging to IL-1 
family, e.g. IL-18.  
Literature data provided evidence that the exposure of keratinocytes cell 
lines to ultraviolet radiation resulted in the activation of pathways involved 
in the innate immune response, such as the inflammasome pathway, which 
leads to the secretion of specific pro-inflammatory cytokines, like IL-1β or 
IL-18 [201]. Interestingly, Dell’Oste and colleagues have demonstrated that 
HPV38, as well as HPV16, were able to block IL-1β secretion  [264]. As 
observed in the transcriptome profile, RT-qPCR showed that the 
expression of the pro-inflammatory cytokine IL-18 was strongly inhibited in 
HPV38 E6/E7 Tg mice when exposed to UVB radiation. In contrast, the 
wild-type mice showed an up-regulation of cytokine expression when 
exposed to the same dose.  
More interestingly, in agreement with the published data obtained by 
Schwarz and colleagues, that provided evidence of the involvement of IL-
18 in DNA repair damage induced by the UV irradiation [217], [218] our 
preliminary results showed that the injection of exogenous rIL-18 into 
HPV38 E6/E7 Tg mice caused a significant delay in the appearance of 
UVB-induced skin lesions. Most likely, the injection of the exogenous 
cytokine into these mice also causes a decrease in the accumulation of 
DNA damage UV-induced, but more experiments are necessary to 
corroborate this hypothesis. This result was in line with the data obtained 
by Trinchieri and colleagues that showed the highest susceptibility of 
Il18−/− and Il18r1−/− mice to develop colitis and polyp compared to wild-
type mice [259], further corroborating the role played by IL-18 in cancer 
development. 
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The results obtained with the in vivo mouse model were confirmed also 
using human primary keratinocytes (HPKs) as an experimental model. 
Even under in vitro condition, we observed an UV-induced upregulation of 
IL-18 mRNA expression in HPKs, as well as of some key inflammasome 
components, such as AIM2 and the adaptor protein ASC, but not of 
NLRP1, which is known to be the most expressed inflammasome in 
keratinocytes [128]. Interestingly, experiments in other cell lines, such as 
immortalized keratinocytes HaCat and NIKs as well as primary 
keratinocytes with extended life span due to the overexpression of hTERT, 
showed high basal levels of IL-18 mRNA levels that were not further 
increased by UV irradiation. However, the presence of the two viral 
oncoproteins significantly down regulated the basal level of IL-18 
expression in HPKs hTERT and NIKs cell lines. Of note, it is known that in 
the cell lines that we used as experimental models p53 status is altered; in 
fact, HPKs hTERT and NIKs [269] showed an accumulation of wild type 
p53 while in HaCat this protein is mutated [270]. Furthermore, it is also 
well-known that UVB radiation caused an accumulation of p53 in HPKs as 
well as the an over-expression of the hTERT gene [265], [266], [271]. In 
order to correlate p53 expression with IL-18 modulation at basal level in 
those cell lines we observed that in our systems high level of p53 
expression corresponded to IL-18 accumulation, an event that was strongly 
appreciated at the mRNA level in HPKs hTERT cell line when compared 
with human primary keratinocytes. 
More interestingly, we found a reduction of IL-18 expression after the 
knockdown of p53 from HPKs hTERT cell line. These findings supported 
our hypothesis that p53 may play a role in the regulation of these events, 
miming the effect of UVB exposure in the up-regulation of the transcription 
of IL-18.  
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It is also well known about the ability of p53 to control the expression of 
target genes by either activating or inhibiting the activity of p53 responsive 
promoters [272]. For instance, p53 can contribute to immune response by 
the direct transactivation of key components of immune signaling pathways, 
i.e. TLR3 or TLR9  in response to cellular stress [273], [274]. Our 
bioinformatics analysis of the IL-18 promoter revealed the presence of 
several putative p53 responsive elements and ChIP experiments confirmed 
that p53 is recruited to IL-18 promoter. Furthermore, this event was 
completely abolished in the hTERT HPKs cell line expressing E6 and E7 of 
HPV38.  
In addition, also the analysis of the promoter activity, through use of a 
vector containing the isolated IL-18 promoter cloned in front of the 
luciferase reporter gene, showed a strong activation of IL-18 promoter in 
hTERT HPKs only in absence of the two viral oncoproteins. 
Interestingly, the analysis of the protein level of IL-18 showed that the 
cytokine was cleaved and released into the supernatant after UVB 
irradiation in all the experimental models used in this study, in accordance 
with the literature data [201], while HPV38 E6 and E7 were able to block 
the cleavage and the consequent release of the protein.  
 
In conclusion, our data clearly demonstrated that E6 and E7 were able to 
interfere with the inflammasome pathway at different levels, leading to a 
complete block of the transcription as well as of the secretion of the pro-
inflammatory cytokine, such as IL-18. In particular, our study provides new 
possible explanations for the cooperation between UV irradiation and β-
HPV types in cellular transformation. 
However, future studies are necessary to further elucidate the mechanisms 
of maturation and secretion of IL-18 and how the virus blocks this event.   
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CONCLUSIONS  
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To date, almost 20% of human cancer worldwide are attributed to the viral 
infection [20]–[22] and in particular the association between HPV and the 
development of cancer has been broadly studied. As reported above, E6 
and E7 are the main players for cancer development since they are able to 
deregulate many cellular events that favor the transformation of infected 
cells [86], [108]. In particular, the evasion of the immune system response 
by the virus is another important key event in cancer progression. In fact, 
many studies have demonstrated the ability of the mucosal HR HPV types 
to inhibit the innate and adaptive immune response but very little is known 
about the impact of viral oncoproteins from β-HPV types on the immune 
surveillance. The inflammasome complexes are important players in the 
innate immune response against viruses but also in this case there is 
limited published data regarding the activation of the immune system in 
keratinocytes [154].  
In the present work, we have provided evidence that the expression of E6 
and E7 oncoproteins from β-HPV38 in human primary keratinocytes causes 
the inhibition of UV-induced inflammasome response, by the alteration of 
the gene expression profile of the host. We demonstrated that the two 
oncoproteins are able to impair the UV-mediated production of protein 
involved in the inflammasome pathway, such as through the downstream 
effector IL-18.  
Here, we also showed a novel mechanism of transcriptional regulation of 
the promoter region of IL-18 mediated by p53. The structure of this 
promoter has been previously characterized and has revealed the presence 
of several putative responsive elements for different transcription factors 
[203], but not for p53. Our findings also exhibited the recruitment of p53 on 
the promoter region, which is completely abolished in presence of the viral 
oncoproteins. Moreover, further studies will need to better understand the 
role of p53 in the regulation of IL-18 promoter.  
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Based on these findings, we could hypothesize that the down regulation of 
IL-18, due to the presence of E6 and E7, may impair the ability of 
keratinocytes to recruit the cells of the immune system to the UV-exposed 
area, causing a defect in the elimination of keratinocytes harboring DNA 
damage. These alterations also may cause an accumulation of UV-induced 
DNA damage and subsequently the development of skin cancer. Together 
these findings provide further lines of evidence for cutaneous β-HPV38 in 
the development of NMSC after UV-exposure.  
Furthermore, more study are necessary to better characterize the 
molecular mechanisms involved in the deregulation of these events 
mediated by HPV38 and possible other β-HPV types.  
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